Synthetic and Natural Inhibitors of Phospholipases A₂: Their Importance for Understanding and Treatment of Neurological Disorders

Wei-Yi Ong,*,† Tahira Farooqui,‡ George Kokotos,§ and Akhlaq A. Farooqui‡

†Department of Anatomy, National University of Singapore, Singapore 119260, Singapore
‡Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, Ohio 43210, United States
§Laboratory of Organic Chemistry, Department of Chemistry, University of Athens, Panepistimiopolis, Athens 15771, Greece

ABSTRACT: Phospholipases A₂ (PLA₂) are a diverse group of enzymes that hydrolyze membrane phospholipids into arachidonic acid and lysophospholipids. Arachidonic acid is metabolized to eicosanoids (prostaglandins, leukotrienes, thromboxanes), and lysophospholipids are converted to platelet-activating factors. These lipid mediators play critical roles in the initiation, maintenance, and modulation of neuroinflammation and oxidative stress. Neurological disorders including excitotoxicity; traumatic nerve and brain injury; cerebral ischemia; Alzheimer's disease; Parkinson's disease; multiple sclerosis; experimental allergic encephalitis; pain; depression; bipolar disorder; schizophrenia; and autism are characterized by oxidative stress, inflammatory reactions, alterations in phospholipid metabolism, accumulation of lipid peroxides, and increased activities of brain phospholipase A₂ isoforms. Several old and new synthetic inhibitors of PLA₂, including fatty acid trifluoromethyl ketones; methyl arachidonyl fluorophosphonate; bromoenol lactone; indole-based inhibitors; pyrrolidine-based inhibitors; amide inhibitors, 2-oxoamides; 1,3-disubstituted propan-2-ones and polyfluoroalkyl ketones as well as phytochemical based PLA₂ inhibitors including curcumin, *Ginkgo biloba* and *Centella asiatica* extracts have been discovered and used for the treatment of neurological disorders in cell culture and animal model systems. The purpose of this review is to summarize information on selective and potent synthetic inhibitors of PLA₂ as well as several PLA₂ inhibitors from plants, for treatment of oxidative stress and neuroinflammation associated with the pathogenesis of neurological disorders.

KEYWORDS: *Phospholipase A₂ inhibitors, eicosanoids, neuroinflammation, oxidative stress, neurological disorders, lipid mediators, lipids, neurodegeneration*

1. INTRODUCTION

1.1. Phospholipases A₂. Phospholipases A₂ (PLA₂) are a class of enzymes that hydrolyze the ester bond at the *sn*-2 position of glycerophospholipids to yield a free fatty acid and a lysophospholipid. The fatty acids that are produced by PLA₂ activity may undergo reacylation to glycerophospholipids, or may be further metabolized to bioactive products. Under physiological conditions, PLA₂ helps to maintain membrane structure and function, by removing oxidized and damaged phospholipids. Under pathological conditions, however, there is increased activity of PLA₂ which lead to increased generation of fatty acids and lysophospholipids, which in turn can be metabolized to second messengers and metabolites that contribute to neuroinflammation and propagation of neuronal injury. For instance, arachidonic acid (AA) is metabolized by cyclooxygenase (COX) and lipoxygenase (LO) into prostaglandins, leukotrienes, thromboxanes, and lipoxins.[1] These mediators are collectively known as eicosanoids and produce a wide range of biological actions. They include potent effects on inflammation, vasodilatation, vasoconstriction, apoptosis, and immune

responses through interactions with eicosanoid receptors.[2] The nonenzymatic oxidation of AA results in the generation of 4 hydroxynonenal, isoprostanes, isoketals and isofurans.[2] These lipid mediators are important biomarkers for lipid peroxidation. The other product of the PLA₂ catalyzed reaction is a lysophospholipid. These are either reacylated into native phospholipids or acetylated to another bioactive mediator known as platelet activating factor (PAF), which also contributes to neuroinflammation.

Some PLA₂s release docosahexaenoic acid (DHA), which is further metabolized by 15-lipoxygenase into docosanoids (resolvins and neuroprotectins, and marsins) that have anti-inflammatory, antioxidant, antiapoptotic and neuroprotective properties[3] (Figure 1). In the brain, DHA modulates and facilitates neurotransmission through its effect on dopaminergic, noradrenergic, glutamatergic and serotonergic neurotransmitter receptors, and insulin, retinoid, and TGF-β receptors.[4] Detailed

Figure 1. Interactions between AA- and DHA-derived metabolites and modulation of oxidative stress and neuroinflammation by docosahexaenoic acid (DHA) and neuroprotectin D1 (NPD1). *N*-Methyl-D-aspartate receptor (NMDA-R); glutamate (Glu); phosphatidylcholine (PtdCho); lyso-phosphatidylcholine (lyso-PtdCho); cytosolic phospholipase A_2 (cPLA$_2$); arachidonic acid (AA); prostaglandins (PGs); leukotrienes (LTs); thromboxanes (TXs); platelet activating factor (PAF); cyclooxygenase2 (COX-2); 5-lipoxygenase (5-LOX); 15-lipoxygenase (15-LOX); plasmalogen (PlsEtn); calcium independent phospholipase A2 (iPLA$_2$); plasmalogen-selective phospholipase A_2 (PlsEtn-PLA2); secretory phospholipase A_2 (sPLA$_2$); inducible nitric oxide synthase (iNOS); reactive oxygen species (ROS); tumor necrosis factor-alpha (TNF-α); interleukin 1beta (IL-1β); interleukin-6 (IL-6); and nuclear factor-κB (NF-κB).

investigations have been performed on neuroprotectin D1 (NPD1) in retinal pigment epithelial cells and brain.[5−9] NPD1 upregulates antiapoptotic proteins (Bcl-2 and Bcl-xL) but downregulates proapoptotic proteins (Bax and Bad) in response to cellular oxidative stress and cytokine activation, leading to an overall pro-survival transcriptome.[5,7−9]

1.2. Classification of Brain PLA$_2$s. Recent advances in molecular and cellular biology have led to the identification of 17 genes and more than 25 mammalian intracellular PLA$_2$ paralogs/splice variants/isozymes in the mammalian brain. PLA$_2$s can be classified into five main types on the basis of their specific features such as sequence, molecular weight, disulfide bonding patterns, and Ca^{2+} dependency. They include isoforms of cytosolic PLA$_2$ (cPLA$_2$), calcium independent PLA$_2$ (iPLA$_2$), secretory PLA$_2$ (sPLA$_2$), plasmalogen selective PLA$_2$ (PlsEtn-PLA$_2$), the platelet activating factor-acetylhydrolases (PAF-AH), and lipoprotein-PLA$_2$ (Lp-PLA$_2$, 45 kDa).[10,11] cPLA$_2$ requires 10 to 1000 nM calcium for binding to a phospholipid substrate. Various isozymes of cPLA$_2$ preferentially hydrolyze AA and are activated by phosphorylation on Ser-505, Ser-727, and Ser-515 mediated by MAPK, MEK1, and calcium- and calmodulin-dependent kinase II, respectively.[12] cPLA$_2$ is expressed at relatively high levels in the hypothalamus, brainstem, cerebellum, and spinal cord of normal rats.[13] Variant isozymes of cPLA$_2$ (cPLA$_2\alpha$,

cPLA$_2\beta$, cPLA$_2\gamma$, cPLA$_2\delta$, cPLA$_2\varepsilon$, and cPLA$_2\zeta$.) have molecular mass of 85−110 kDa and are involved in signal transduction processes. cPLA$_2\alpha$ has been mapped to chromosome 1, cPLA$_2\beta$ to chromosome 15, and cPLA$_2\gamma$ to chromosome 19. Amino acid sequencing indicates that cPLA$_2\beta$ and cPLA$_2\delta$ have 120 and 135 amino acid inserts, respectively, between the C2 domain and catalytic domain A, whereas in cPLA$_2\alpha$ the two domains are adjacent to each other. In addition, cPLA$_2\beta$ has a unique N-terminal region composed of 242 amino acids, which is not required for enzymatic activity.[14] Most cPLA$_2$ isozymes prefer AA over other fatty acids and do not use Ca^{2+} for catalysis, although submicromolar Ca^{2+} concentrations are needed for membrane binding. cPLA$_2$ isoform (particularly cPLA$_2\alpha$) activity is regulated by a number of protein kinases, which phosphorylate cPLA$_2\alpha$ on different serine residues. For example, Ser 505 is phosphorylated by extracellular signal-regulated kinases (ERK1/2) and p38 mitogen-activated protein kinase (MAPK), Ser 515 by Ca^{2+}/calmodulin-dependent protein kinase II (CaMKII), and Ser 727 by MAPK-interacting kinase (MNK1) or a closely related isoform.[15,16]

iPLA$_2$s are active without calcium and preferentially hydrolyze docosahexaenoic acid (DHA) from neural membrane phospholipids. They have a molecular mass of 80 kDa. These enzymes are involved in not only signal transduction processes but also

phospholipid remodeling. Besides PLA$_2$ activity, isoforms of iPLA$_2$ exhibit lysophospholipase and transacylase activities.[17] iPLA$_2\alpha$, iPLA$_2\beta$, and iPLA$_2\gamma$ release fatty acids, while other iPLA$_2$ isoforms δ, ε, ξ, and η display triglyceride lipase and transacylase activities.[18] In addition, iPLA$_2\beta$ expresses an acyl-CoA thioesterase activity.[19] Members of the iPLA$_2$ family share homology with patatin, a lipid hydrolase with an unusual folding topology that differs from classical lipases. iPLA$_2$ is stabilized by ATP,[20] and the iPLA$_2\beta$ sequence contains a consensus nucleotide binding motif (GXGXXG) which is homologous to the nucleotide binding motif of protein kinases.[21] iPLA$_2\gamma$ plays an important role in regulation of glutamate receptor functions, long-term potentiation and depression, neuronal plasticity, and neurodegenerative processes.[22−24]

sPLA$_2$ isoforms have molecular mass (14−18 kDa) and are mainly associated with synaptosomes and the synaptic vesicle fraction.[25] They require millimolar concentrations of calcium and have no substrate specificity for fatty acids. Multiple forms of sPLA$_2$ exist, including sPLA$_2$-IB, sPLA$_2$-IIA, sPLA$_2$-IIC, sPLA$_2$-IID, sPLA$_2$-IIE, sPLA$_2$-IIF, sPLA$_2$-III, sPLA$_2$-V, sPLA$_2$-X, sPLA$_2$-XIIA, and sPLA$_2$-XIIB. sPLA$_2$ isoforms have 5−8 disulfide bonds. Phospholipid hydrolysis proceeds with the interaction of a water molecule through hydrogen bonding to the active site histidine residue. Adjacent to the histidine is a conserved aspartate residue at the catalytic dyad, which together with the calcium-binding loop, acts as a ligand cage for calcium. Isoforms of sPLA$_2$ are present in all regions of the mammalian brain. The highest activities of sPLA$_2$ are found in medulla oblongata, pons, and hippocampus, moderate activities in the hypothalamus, thalamus, and cerebral cortex, and low activities in the cerebellum and olfactory bulb.[26]

PlsEtn-PLA$_2$ hydrolyzes DHA from plasmalogen, a unique class of neural membrane phospholipids that has a long chain vinyl ether linkage at the *sn*-1 position of the glycerol moiety. This enzyme has a molecular mass of 39 kDa and does not require calcium for its activity.[27−29] No isoforms of PlsEtn-PLA$_2$ have been reported in the brain, and the enzyme is inhibited by bromoenol lactone. C2 ceramide stimulates PlsEtn-PLA$_2$ activity in a dose-dependent manner. However, at higher concentration, PlsEtn-PLA$_2$ activity is inhibited. Like ceramide, ceramide 1-phosphate stimulates PlsEtn-PLA$_2$ activity in a dose-dependent manner, and dihydroceramide, the inactive analog of C2 ceramide, has no effect on PlsEtn-PLA$_2$ activity.[29]

PAF acetyl hydrolase (PAF-AH, 26−45 kDa) selectively hydrolyzes short acyl chains (C2 to C9) at the *sn*-2 position of (PtdCho) or PtdEtn. This enzyme shows no activity with acyl chains longer than C9, but an unusual *sn*-2 acyl group containing a carbonyl group at the ω-end of the acyl chain acts as the substrate for this enzyme. Unlike cPLA$_2$ and sPLA$_2$, PAF-acetyl hydrolase is not an interfacial enzyme and has broad substrate specificity as an esterase. PAF-AH hydrolyzes PAF, its analogs, and short chain oxidized phospholipids in a calcium-independent manner. These substrates are more water-soluble than two long fatty acyl chains of native phospholipids that are interfacially hydrolyzed by cPLA$_2$ and sPLA$_2$.[30]

Lipoprotein-PLA$_2$ (Lp-PLA$_2$, 45 kDa) is found in blood circulation and is associated with apo-B100 of LDL. Elevated levels of Lp-PLA$_2$ are associated with coronary heart disease, stroke, and dementia.[10]

1.3. Significance of Paralogs/Splice Variants/Isozymes of PLA$_2$. The significance of occurrence of paralogs/splice variants/isozymes of PLA$_2$ in the brain is not fully understood. Studies to unveil the mechanisms of action of PLA$_2$ and factors

regulating their activities in normal physiological and pathophysiological functions have demonstrated cross-talk among different groups of PLA$_2$s.[10,11,25] Thus, in brain tissue, PLA$_2$ isozymes are part of a complex signal transduction network through generation of lipid mediators. The activity of PLA$_2$ isozymes in neural cells is the rate-limiting step for release of AA and production of inflammatory lipid mediators (eicosanoids, lysophosphatidic acid, and platelet activating factor)[31] or DHA and derived anti-inflammatory lipid mediators (docosanoids and lipoxins). These processes provide neural cells with great versatility in ensuring that AA, DHA, and their oxygenated metabolites are efficiently utilized. In brain tissue, PLA$_2$ isozymes do not function interchangeably, but act in parallel to transduce signals among neurons, astrocytes, and microglial cells. It is likely that multiple forms of PLA$_2$ act on different cellular pools of phospholipid molecular species located in various subcellular organelles. The activity of PLA$_2$ isozymes may depend not only on structural, physicochemical, and dynamic properties of neural membranes but also on the interaction of extracellular signal with PLA$_2$-linked neural cell receptors such as dopamine, glutamate, serotonin, P2-purinergic, cytokine, and growth factor receptors.[25,32,33]

Overstimulation of glutamate receptors results in activation of NADPHoxidase (Nox). This leads to activation of PLA2 and generation of AA, and further metabolism of AA results in formation ROS and neuroinflammation in neurological disorders.[25,34,35] Brain cells are susceptible to the injurious effects of ROS. The latter also act as a signaling molecule to trigger inflammatory responses in the brain through the activation of the redox-sensitive transcription factors, including nuclear factor-κB (NF-κB) and activator protein-1 (AP-1).[36,37] Together, results indicate that members of the PLA$_2$ superfamily are involved in the synthesis of lipid mediators that have been implicated in fundamental cellular responses including growth, neuronal excitation, differentiation, adhesion, migration, inflammation, neurotransmitter exocytosis, cognitive and behavioral function, and apoptosis.[11,25,33,38]

1.4. Roles of PLA$_2$ in Neurodegeneration in Neurotraumatic, Neurodegenerative, and Neuropsychiatric Disorders. Under normal conditions, PLA$_2$ isozymes are involved in generation of lipid mediators that are closely associated with phospholipid turnover, neurotransmitter release, long-term potentiation, memory processes, membrane repair, ion channel function, and gene transcription processes.[39] In pathological conditions, however, increased degradation of phospholipids due to activation of PLA$_2$ isozymes leads to changes in membrane permeability and stimulation of enzymes involved in lipolysis, resulting in disruption of membrane structure.[32,33] Together with alterations in activities of membrane bound-enzymes, receptors, and ion channels, this produces nervous system dysfunction and cognitive impairment.[25,40,41] The effects are closely associated with the activation of microglia and astrocytes, which release inflammatory cytokines (TNF-α, IL-1β, and IL-6). These propagate and intensify neuroinflammation by a number of mechanisms including further upregulation of PLA$_2$, generation of platelet-activating factor, and stimulation of nitric oxide synthase.[4] High levels of free radicals, lipid peroxides, and eicosanoids in brain produce oxidative stress and inflammation, and these processes along with compromised energy metabolism may play a role in neurotraumatic (excitotoxicity, traumatic nerve and brain injury, cerebral ischemia), neurodegenerative/neuroimmune (Alzheimer disease, Parkinson disease, multiple sclerosis or

experimental allergic encephalitis; and prion diseases), chronic pain, and neuropsychiatric diseases (depression, schizophrenia, and autism).[25,42]

For treatment of the above neurotraumatic, neurodegenerative, and neuropsychiatric disorders, development of selective inhibitors of PLA$_2$ isozymes is very important. An ideal PLA$_2$ inhibitor not only should be able to inhibit neuroinflammation and block oxidative stress but also should cross the blood brain barrier (BBB). Inhibitors must reach the site where inflammatory processes are taking place for better efficiency,[25] and this may be achieved through better drug delivery systems that target the brain, or protect PLA$_2$ inhibitors from *in vivo* degradation or detoxification. The effects of PLA$_2$ inhibitors on genes and lipids can be monitored by microarray and lipidomic analyses. These studies can lead to better therapeutic agents for the treatment of neurological disorders involving glycerophospholipid alterations.

2. SYNTHETIC INHIBITORS OF PLA$_2$

2.1. Fluoroketones and Fluorophosphonates. Arachidonoyl trifluoromethyl ketone (**1**, AACOCF$_3$) was the first


inhibitor of cPLA$_2$ reported in the literature.[43,44] It is a slow, tight binding inhibitor of cPLA$_2$, presenting 4 orders of magnitude more potent inhibition of this enzyme, compared to sPLA$_2$. AACOCF$_3$ inhibits cPLA$_2$ with an $X_I(50)$ value of 0.036 as determined using a mixed micelle assay.[45] The trifluoromethyl ketone analogues of palmitic (**2**), γ-linolenic (**3**), and linoleic acid (**4**) were also found to inhibit cPLA$_2$.[45,46] In contrast to cPLA$_2$, the saturated fatty acid derivative **2** is 4-fold more potent for iPLA$_2$ than AACOCF$_3$ (X_I (50) values 0.0075 and 0.028, respectively). It is clear, however, that AACOCF$_3$ is not a selective inhibitor, and AACOCF$_3$ (**1**) and palmitoyl trifluoromethyl ketone (**2**) also inhibit macrophage Ca^{2+}-independent PLA$_2$.[47] In addition, AACOCF$_3$ inhibits other enzymes such as COX.[48] Thus, any results obtained by using AACOCF$_3$ in cells and *in vivo* must be interpreted with caution.

AACOCF$_3$ has been reported to modulate pathogenesis of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis.[49] In addition, intracerebroventricular injection of AACOCF$_3$ significantly reduces responses to von Frey hair stimulation, 8 h and 1 day after facial carrageenan injection.[50] Intrathecal injection of AACOCF$_3$ dose-dependently modulates thermal hyperalgesia induced by carrageenan as well as formalin injections.[51] cPLA$_2$ is also proposed to be involved in prion disease, and daily treatment of prion-infected cell lines with AACOCF$_3$ for 7 days prevents accumulation of protease-resistant prion protein (PrPres).[52] Moreover, cPLA$_2$ reduction by AACOCF$_3$ ameliorates cognitive deficits in a mouse model of Alzheimer's disease.[53]

Kokotos, Dennis and co-workers developed a variety of polyfluoroketones.[54−56] Pentafluoroethyl ketone FKGK11 (**5**) was found to be a selective iPLA$_2$ inhibitor ($X_I(50)$ 0.0014),[55] while the trifluoromethyl ketone FKGK2 (**6**) is considered a pan-inhibitor of iPLA$_2$ ($X_I(50)$ 0.0169), cPLA$_2$ ($X_I(50)$ 0.0098), and even sPLA$_2$.[54] Structure−activity relationship studies led to the potent iPLA$_2$ inhibitor FKGK18 (**7**) ($X_I(50)$ 0.0002), which is 195 and >455 times more potent for iPLA$_2$ than for cPLA$_2$ and

GV sPLA$_2$, respectively, making it a valuable tool to explore the role of iPLA$_2$ *in vitro* and *in vivo*.[55]

Recently, pentafluoroethyl ketone GK187 (**8**) was developed as the most potent inhibitor of iPLA$_2$ ever reported ($X_I(50)$ 0.0001).[56] Deuterium exchange mass spectrometry and molecular dynamics simulations show that the fluoroketone inhibitor **9** forms favorable interactions inside the active-site pocket iPLA$_2$ and blocks the entrance of phospholipid substrates.[57]

The polyfluoroketones, together with other selective PLA$_2$ inhibitors, for example 2-oxoamides, have been used to clarify the role of each PLA$_2$ class in neurological disorders.[58,59] For example, the role of various PLA$_2$ isoforms in the progression of EAE has been determined, using the inhibitors FKGK11, AX059, and FKGK2.[59] Inhibition of iPLA$_2$ by FKGK11 shows that the enzyme is a target for vasopressin signaling in the thick ascending limb of the kidney.[60]

Various reports, summarized in a recent review,[61] suggest that iPLA$_2$ plays an essential role in β-cell programmed cell death, and inhibitor FKGK18 is proposed as a candidate drug for prevention of β-cell apoptosis and diabetes.[62] Most recently, FKGK18 and a selective cPLA$_2$ inhibitor are used to discriminate between phospholipid pools of cPLA$_2$ and iPLA$_2$.[63]

Methyl arachidonyl fluorophosphonate (**10**, MAFP), another AA analog, is a potent irreversible cPLA$_2$ inhibitor without affecting human sPLA$_2$.[64] Intrathecal administration of MAFP dose dependently prevents thermal hyperalgesia induced by intraplantar carrageenan as well as formalin-induced flinching.[65]

2.2. Bromoenol Lactone. Bromoenol lactone (**11**, BEL) is an irreversible, covalent inhibitor of iPLA$_2$ (IC$_{50}$ 60 nM).[47,66] It has shown a 1000-fold selectivity for iPLA$_2$ versus cPLA$_2$ and sPLA$_2$,[67] and thus it is considered a selective inhibitor of this enzyme and is commonly used to inhibit iPLA$_2$ in cellular systems. BEL is usually present as a racemate; however, the (R)- and (S)-enantiomers of BEL have different enzyme inhibitory properties.[68−70] (S)-BEL inhibited iPLA$_2\beta$ 10-fold more potently than (R)-BEL, while (R)-BEL inhibited iPLA$_2\gamma$ almost 10-fold more potently than (S)-BEL.[68,70] BEL inactivates iPLA$_2$ by generating a diffusible bromomethyl keto acid that alkylates cysteine thiols, rather than interacting with the active-site serine.[71] Recently, mass spectrometry studies demonstrate a highly reactive cysteine residue (C651) that interacts with the active site of the enzyme.[72]

It is, however, noted that BEL also inhibits enzymes such as serine protease[73] magnesium-dependent phosphatidate phosphohydrolase-1,[73] and the possibility that BEL may be inhibiting these enzymes besides iPLA$_2$ must be considered when interpreting experiments using this inhibitor.


11

Studies using BEL report that prostaglandin E2 (PGE$_2$) generation may be partially mediated by iPLA$_2$, in addition to sPLA$_2$.[74] BEL reduces AA release and PGE$_2$ production upon stimulation in 3T6 fibroblast cultures.[75] In addition, BEL selectively increases AMPA receptor-mediated synaptic transmission.[76] Intracerebroventricular injection of BEL reduces responses to von Frey hair stimulation after facial carrageenan injection in both C57BL/6J (B6) and BALB/c mice.[50] BEL also decreases prostate cancer cell growth by p53-dependent and independent mechanisms[77] and activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells.[78] These findings may provide some insights into signaling mechanisms involving iPLA$_2$ in the brain.

2.3. Indole-Based Inhibitors. A highly potent sPLA$_2$ inhibitor having a novel indole structure was discovered by

12, R=H Varespladib
**13**, R=Me Varespladib methyl

14, LY311727

high-volume screening at Lilly, which cocrystallizes with human recombinant sPLA$_2$ and interacts with its active site.[79] Extensive work on indole-based inhibitors led to the development of varespladib (**12**) and varespladib methyl (**13**), which functions as a pro-drug of varespladib. Varespladib is a potent inhibitor of human sPLA$_2$ GIIA (IC$_{50}$ 0.009 μM), which inhibits human GIB pancreatic sPLA$_2$ with an IC$_{50}$ value of 0.228 and is inactive against cPLA$_2$ and COX.[80,81] Thus, varespladib (**12**) was selected for evaluation clinically as a sPLA$_2$ inhibitor. Another indole-based inhibitor is LY311727, which inhibits sPLA$_2$ with an IC$_{50}$ value of 0.023 μM.[82]

Varespladib reached Phase II clinical trials for treatment of severe sepsis, but was terminated because efficacy was poorer than expected (http://clinicaltrials.gov/, Identifier: NCT00034476). Later, Anthera Pharmaceuticals disclosed varespladib and varespladib methyl as sPLA$_2$ inhibitors for the treatment of cardiovascular diseases,[83,84] but Phase III clinical trials were terminated in 2012 due to inability of the study to detect a statistically significant benefit of the drug.

Another series of very important and potent cPLA$_2$ inhibitors was developed by Wyeth, which include indole compounds such as **15–18**.[85,86] Ecopladib inhibits cPLA$_2$ with IC$_{50}$ values of 0.15 μM using a GLU assay and 0.11 μM using an RWB assay, while efipladib presented IC$_{50}$ 0.04 μM in a GLU assay and 0.07 μM in

an RWB assay. WAY-196025 is even more potent (IC$_{50}$ 0.01 μM in a GLU assay and 0.03 μM in an RWB assay).

15, Ecopladib, X=O, R$_1$=H, R$_2$=R$_3$=Cl
16, Efipladib, X=CH$_2$, R$_1$=H, R$_2$=R$_3$=Cl
**17**, Giripladib, X=CH$_2$, R$_1$=CF$_3$, R$_2$=R$_3$=H

18, WAY-196025

Ecopladib (**15**) shows oral efficacy in inflammation models and advanced to phase I clinical trials, while efipladib (**16**) shows oral efficacy *in vivo*. Giripladib (**17**) was the most promising indole-based inhibitor and advanced to phase II clinical trial for osteoarthritis, but in 2007 the trial was terminated due to gastrointestinal and lipase events (http://clinicaltrials.gov/, Identifier: NCT00396955). Efipladib decreases nociceptive responses without affecting PGE$_2$ levels.[87]

2.4. Pyrrolidine-Based Inhibitors. Shionogi identified a series of pyrrolidine-based inhibitors of PLA$_2$.[88]

19

20

Studies on such derivatives[89−91] show that pyrrophenone (**19**) is a potent and reversible inhibitor of human cPLA$_2$ (IC$_{50}$ 4.2 nM) that strongly inhibits AA release, PGE$_2$, and thromboxane B2 and leukotriene B4 formation in human whole blood.[90,91] A structurally related inhibitor, pyrroxyphene (**20**) presents an IC$_{50}$ value of 0.078 μM and in cellular assays suppresses AA release and PGE2 synthesis from A23187 stimulated THP-1 cells with IC$_{50}$ values of 0.32 and 0.26 μM, respectively.[91] It displays antiarthritic and antibone destructive action in a mouse arthritis model.[92] It is possible that these inhibitors may also be effective against brain cPLA$_2$.

2.5. Amide Inhibitors. A variety of amides based on non-natural amino acids have been reported as inhibitors of sPLA$_2$. FPL67047XX (**21**) is a potent inhibitor presenting an IC$_{50}$ value against human platelet sPLA$_2$ of 21 nM,[93] and binding interactions with human nonpancreatic sPLA$_2$ were demonstrated by high-resolution X-ray crystallography.[94] Another amide inhibitor is based on D-tyrosine.[95] Inhibitor **22** (IC$_{50}$ 0.029 μM) cocrystallizes with sPLA$_2$, and the crystal structure reveals chelation to a Ca^{2+} ion through carboxylate and amide oxygen atoms, H-bonding through an amide NH group to His48,

21, FPL67047XX

22

23, GK115

multiple hydrophobic contacts, and a T-shaped aromatic group–His6 interaction.[95] Oral or intravenous administration of this inhibitor protects the rat small intestine from ischemia reperfusion injury[96] and TNBS-induced colitis.[97] It also exhibits antifibrotic activity in young spontaneously hypertensive rats[98] and preserves bone architecture following ovariectomy in adult rats.[99] Another study reveals amide **23** (GK115), based on (R)-γ-norleucine, as a selective inhibitor of sPLA$_2$ ($X_I(50)$ 0.003) that does not have significant inhibition against cPLA$_2$ or iPLA$_2$.[100] It is interesting to note that its enantiomer is inactive against all three PLA$_2$s (sPLA$_2$, cPLA$_2$, and iPLA$_2$).

GK115 improves locomotor function when administered 1 h after spinal cord injury, compared to vehicle controls.[101]

2.6. 2-Oxoamides. 2-Oxoamides were designed to target the active site serine of cPLA$_2$.[102−106] Long chain 2-oxoamides based

24, n=1,2
m=13

25, AX048

26, AX059

27, GK126

on γ- or δ-amino acids (**24**) containing a free carboxyl group are potent and selective inhibitors of cPLA$_2$, while the corresponding esters inhibit both cPLA$_2$ and iPLA$_2$. The location of the 2-oxoamide inhibitor AX007 ($X_I(50)$ 0.009)[103] in the active site of cPLA$_2$ was determined by a combination of deuterium exchange mass spectrometry with molecular dynamics.[107] Long chain 2-oxoamides based on α-amino acids, for example compound **27**, exhibit inhibitory activity to sPLA$_2$ (IC$_{50}$ 300 nM for human sPLA$_2$ GIIA and 180 nM for mouse sPLA$_2$ GIIA).[108]

Inhibitor AX048 (**25**) ($X_I(50)$ 0.022 for cPLA$_2$ and $X_I(50)$ 0.027 for iPLA$_2$) is able to block spinal PGE$_2$ release and shows potent antihyperalgesic effect.[109] In addition, inhibitor AX059 demonstrates selective cPLA$_2$ inhibitory activity ($X_I(50)$ 0.008) and modulates inflammation and degeneration by promoting regulatory T cells in rats with EAE.[110]

28

29

2.7. 1,3-Disubstituted Propan-2-ones. Astra Zeneca developed a series of potent inhibitors of cPLA$_2$ based on a 1,3-disubstituted propan-2-one skeleton.[111] Compound **28**, which contains a decyloxy lipophilic side chain and a benzoic acid group, inhibits cPLA$_2$ with an IC$_{50}$ value of 0.008 μM in a bilayer assay, 0.03 μM in a soluble assay, and 2.8 μM in a whole cell assay. Later, Lehr and co-workers presented a series of articles describing 1,3-disubstituted propan-2-one derivatives mainly incorporating an indole ring.[112−116]

Extended structure–activity relationship studies, on the influence of the position of the carboxylic acid group, the nature of the substituent of the indole ring, the introduction of a second substituent in position 3 of the indole ring, and the substitution of the octyl chain by a decyloxy chain, led to derivative **29**. This inhibitor presents an IC$_{50}$ of 0.0043 μM in a vesicle assay with isolated cPLA$_2$ enzyme.

2.8. Natural Products. The natural product manoalide (**30**), isolated in the early 1980s from the sponge Luffariella variabilis,

30

31

was reported to be the first inhibitor of cobra venom sPLA$_2$.[117] Manoalide reached phase II clinical trials as a topical antipsoriatic. However, its development was discontinued because of formulation problems.[118] Scalaradial (**31**), as well as 12-epi-scalaradial, are marine products that inhibit sPLA$_2$ and present in vivo anti-inflammatory activity.[119] Scalaradial has been demonstrated to inhibit human recombinant sPLA$_2$ GIIA (IC$_{50}$ 0.07 μM), but not cPLA$_2$.[120]

2.9. Other Inhibitors. Some other compounds have been claimed as PLA$_2$ inhibitors, but they are in general weak and not selective inhibitors and the mechanism of their action is not known. Thus, the interpretation of the in vivo effects of the inhibitors described in this section 2.9 has to be considered with caution.

The antimalarial drug quinacrine (**32**) has been employed *in vivo* as an inhibitor of PLA$_2$, and attenuation of the release of AA in different cell lines has been demonstrated.[121] However, it is a nonspecific inhibitor that is able to inhibit both cPLA$_2$ and sPLA$_2$.[122] 7,7-Dimethyl-5,8-eicosadienoic acid (DEDA) is an AA analog that has been reported to inhibit macrophage PLA$_2$ activity with an IC$_{50}$ of 16 μM.[123]

The nonapeptide CHEC-9 (CHEASAAQC) inhibits sPLA$_2$ and has been shown to inhibit neuron death and inflammation.[124] PX-18 (**33**) is a lipid compound and a nanocrystal formulation based on it presenting neuroprotective effects in cerebral ischemia/repefusion in gerlbils.[125] EPC-K1, a phosphate diester of α-tocopherol and ascorbic acid, has been reported to weakly inhibit sPLA$_2$ activity in human plasma in a concentration-dependent manner (IC$_{50}$ 730 μM[126]).

3. ROLE OF PLA$_2$ INHIBITION IN NEUROLOGICAL CONDITIONS

3.1. Excitotoxicity. The binding of excitatory amino acids such as glutamate to NMDA, AMPA, and kainate classes of glutamate receptors leads to activation of PLA$_2$, release of AA from membrane lipids, free radical damage, inflammatory responses, and neuronal injury.[127,128] In return, PLA$_2$ activity can lead to increased exocytosis of neurotransmitters and may further propagate excitotoxicity.[129] All classes of PLA$_2$ inhibitors are effective in reducing glutamate and aspartate release into the extracellular milieu. The protein kinase C (PKC) inhibitor chelerythrine chloride reduced excitatory amino acid efflux, while

Figure 2. Chemical structures of active components of *Centella asiatica*, EGb 761, and curcumin. *Centella asiatica* contains triterpene saponoside (R$_1$ = H; R$_2$ = CH$_2$OH; R$_3$ = H), castilliferol, and isochlorogenic acid; EGb 761 contains glycosides of the flavonols quercetin, isorhamnetin, and kaempferol, the terpene-lactones bilobalide and ginkgolides A, B and C, M, J, and bilobalide, and ginkgolic acid. Curcumin powder contains many polyphenols.

Figure 3. Modulation of neuroinflammation and oxidative stress by *Centella asiatica*, EGb 761, and curcumin. Arachidonic acid (AA). *N*-Methyl-D-aspartate receptor (NMDA-R); Glutamate (Glu); Phosphatidylcholine (PtdCho); cytosolic phospholipase A_2 (cPLA$_2$); lysophosphatidylcholine (lyso-PtdCho); cyclooxygenase (COX); lipoxygenase (LOX); arachidonic acid (AA); platelet activating factor (PAF); reactive oxygen species (ROS); nuclear factor-κB (NF-κB); nuclear factor-κB-response element (NF-κB-RE); inhibitory subunit of NF-κB (I-κB); tumor necrosis factor-α (TNF-α); interleukin-1β (IL-1β); interleukin-6 (IL-6); inducible nitric oxide synthase (iNOS); secretory phospholipase A_2 (sPLA$_2$);Mito (mitochondria); and Positive sign indicates stimulation.

the PKC activator phorbol 12-myristate 13-acetate (PMA) enhanced their release.[130] In addition, sPLA2-IIA is itself released from neuron-like SH-SY5Y neuroblastoma cells after kainate receptor activation, in a PKC dependent manner.[131] PLA$_2$ activity is itself upregulated after cells are exposed to glutamate. Brief exposure to a calcium ionophore or phorbol 12-myristate 13-acetate stably enhances PLA$_2$ activity, and downregulation of protein kinase C activity partially blocked glutamate's effects.[132,133]

Injection of the potent glutamate analog and excitotoxin, kainate, in rats results in seizures, upregulation of cPLA$_2$ mRNA expression,[129] and induction of cPLA$_2$ immunoreactivity in damaged neurons and reactive astrocytes of the hippocampus.[134] This is accompanied by increased cPLA$_2$ activity[26] and accumulation of the toxic lipid peroxidation product 4-hydroxynonenal, in lesioned areas.[135] Excitotoxicity is reduced by the cPLA$_2$ inhibitor, AACOCF$_3$, but not the iPLA$_2$ inhibitor BEL, in hippocampal slice cultures.[129] Damage is also reduced by treatment with some antimalarial drugs which are nonselective PLA$_2$ inhibitors.[136] As in kainate lesions, injection of iron chloride in the amygdala in rats induces seizures, upregulation of PLA$_2$, and elevated lipid peroxidation products.[137] sPLA$_2$ IIA is

also activated in cortical neurons after stimulation of *N*-methyl-D-aspartate glutamate receptors (NMDA-R). Activation is dependent on Ca^{2+} and reactive oxygen/nitrogen species, and inhibition prevents neuronal apoptotic death.[138]

Studies have been carried out to explore the potential use of botanicals in excitotoxicity. *Ginkgo biloba* extract (EGb761), which contains many ginkgolides, flavonoids, and bilobalides (Figure 2), modulates glutamate and hydrogen peroxide induced increase in expression and activation of cPLA$_2$ and neuronal death after excitotoxicity. The extracellular signal-regulated kinase 1/2 9 (ERK1/2) signaling pathway is involved in EGb761's effect on modulation of cPLA$_2$ activation.[139] Another phytochemical which is reported to affect cPLA$_2$ activity is *Centella asiatica*. The latter is widely distributed in South America and Asia and is known as a therapeutic agent for improving memory and treatment of neurological disorders. Extracts contain triterpene saponoside, castilliferol, and isochlorogenic acid (Figure 2) that dose-dependently inhibits the activity of brain PLA$_2$, suggesting they may be useful in neurological conditions associated with increased activity of the enzyme[140] (Figure 3).

3.2. Traumatic Nerve and Brain Injury. Induction of PLA$_2$ expression occurs after traumatic nerve or brain injury, which may lead to formation of lipid mediators and propagation of injury. Intracellular cPLA$_2$ and iPLA$_2$ also play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury.[101] Increased cPLA$_2$ immunoreactivity is observed in the septum after experimental axonal injury induced by fimbria-fornix transection. The increase is accompanied by accumulation of toxic AA peroxidation product, 4-hydroxynonenal (4-HNE) in target neurons of injured axons. Both cPLA$_2$ and 4-HNE immunoreactivity are blocked by intraperitoneal injections of the nonselective PLA$_2$ inhibitor, quinacrine. Results demonstrate the importance of PLA$_2$ in generation of AA metabolites, which may result in injury of postsynaptic neurons after axotomy.[141] Experimental transection of the fimbria-fornix in rats which leads to interruption of nerve projections from the septum to the hippocampus and vice versa, and fluid percussion injury of the brain, increases levels of 4-HNE, suggesting the harmful effects on neurons.[142] sPLA$_2$ also plays a role in axonal injury. An internal fragment of the human neuroprotective polypeptide DSEP (Diffusible Survival Evasion Peptide) CHEASAAQC or CHEC-9, that inhibits the enzymatic activity of secreted PLA$_2$ (sPLA$_2$), modulates inflammatory responses and preserves neurons after stab injury of the cortex.[143] In contrast to an increase in cPLA$_2$ and sPLA$_2$, a decrease in iPLA$_2$ appears to have a deleterious effect in traumatic brain injury. Dietary supplementation with a curcumin (diferuloylmethane) derivative (Figure 3) restores iPLA$_2$ expression and counteracts the effects of fluid percussion injury, possibly by upregulating mediators necessary for recovery from injury.[142]

PLA$_2$ also plays a role in spinal cord injury.[144] Total PLA$_2$ activity and cPLA$_2\alpha$ protein expression are increased, and upregulation of sPLA$_2$-IIA and IIE occurs 4 h after injury. This could result in formation of secondary mediators that induce loss of oligodendrocytes and propagation of injury.[145] Blocking cPLA$_2$ at 30 min after spinal cord injury, or cPLA$_2$ knockdown, reduces motor deficits and cell loss, indicating a neuroprotective effect.[146]

3.3. Cerebral Ischemia. PLA$_2$ enzymes appear to play an important role in damage to neural tissue after cerebral ischemia. An inhibitor of lipid peroxidation and of PLA$_2$ activity, EPC-K1 reduces deficits in spatial learning when given immediately or 30 min after the onset of reperfusion.[147] The nonselective PLA$_2$ inhibitor, quinacrine (5 mg/kg), also reduces infarct areas in the caudate putamen compared to saline treated rats.[148] Both p38 MAPK and cPLA$_2$ activation are markedly increased 1 day after reperfusion, and intracerebroventricular administration of a P38 MAPK inhibitor, SB203580, suppresses activation of cPLA$_2\alpha$ and attenuates BBB leakage and subsequent edema.[149] COX-2 induction and PGE$_2$ concentration are also greater in cPLA$_2\alpha$ +/+ compared to the cPLA$_2\alpha$ −/− ischemic cortex,[150] and neuronal swelling in ischemic regions is also greater in cPLA$_2\alpha$ +/+ than cPLA$_2\alpha$ −/− mouse brains.[151] In addition, the cPLA$_2$ inhibitor AACOCF$_3$ reduces brain PLA$_2$ activity and cortical and whole hemispheric infarct volume, compared to vehicle treatment.[151]

cPLA$_2$ expression is affected by statins. Treatment of rats that had undergone middle cerebral artery occlusion (MCAO) with a statin, atorvastatin significantly reduced brain water content and infarct sizes; in addition, expression of p38MAPK, phospho-p38MAPK, cPLA$_2$, and 12/15-LOX are decreased, suggesting the role of glycerophospholipid mediators in neuroprotective effects of statins.[152] In addition, the antidepressant nortriptyline

induces a decrease in cPLA$_2$ mediated AA release, through attenuation of both PKC and Erk1/2 kinase expression in primary astrocyte cultures exposed to oxygen glucose deprivation.[153] Results indicate a role of cPLA$_2$, and potential clinical use of inhibitors of the enzyme in cerebral ischemia.

Upregulation of sPLA$_2$ is also reported after cerebral ischemia.[154] An sPLA$_2$ inhibitor, 7,7-dimethyleicosadienoic acid (DEDA), administered following ischemia reperfusion injury attenuates the activity of sPLA$_2$ and levels of lipid peroxidation products, reduces BBB leakage and infract volume, and improves neurological functions.[155] In addition, intraperitoneal injection of nanocrystals of the sPLA$_2$ inhibitor PX-18 reduces neuronal death, DNA damage, and glial activation after ischemia reperfusion induced neuronal injury.[125] PX-18 nanosuspension also preserves cerebrovascular reactivity to stimuli.[156] Results indicate that sPLA$_2$-derived oxidative products contribute to neurovascular damage and that treatment with DEDA or PX-18 reduces secondary injury.

Studies have been carried out to explore the potential use of botanicals for treatment of cerebral ischemia. Baicalein (5,6,7-trihydroxyflavone) originally isolated from the roots of *Scutellaria baicalensis* is an antioxidant and anti-inflammatory agent and was found to improve neurological deficit, reduce brain water content and infarct sizes, and downregulate the expression of 12/15-LOX, p38 MAPK, and cPLA$_2$ after MCAO.[152]

3.4. Alzheimer's Disease. Alzheimer's disease (AD) is a neurodegenerative disease, characterized by memory loss and other cognitive impairments. Two pathologic hallmarks of the disease are extracellular deposits of amyloid β (Aβ) and the presence of neurofibrillary tangles, consisting of hyperphosphorylated tau. There is evidence that cPLA$_2$ is a contributor to the neurodegenerative mechanisms of AD.[157] Analyses of cerebrospinal fluid glycerophospholipids showed a significant increase in the LPC-to-PC ratio, indicating increased PLA$_2$ activity in late onset Alzheimer's disease.[158] Aβ activates NADPH oxidase[159] and enhances protein expression and phosphorylation of cPLA$_2$ and AA release by the NO signaling pathway.[160] Treatment of rat cortical neurons with low concentrations of soluble Aβ (1−40) or Aβ (1−42) results in early calcium-dependent release of AA. Both cPLA$_2$ antisense oligonucleotides and a selective inhibitor of cPLA$_2$ activity abolish the AA release from neurons and protect cells against apoptosis induced by Aβ. Inhibitors of PKC, p38, and MEK/ERK pathways that are involved in cPLA$_2$ phosphorylation and activation reduce Aβ-induced cell death.[161] Aβ also induces activation of sphinogomyelinases and cell death, and these effects are inhibited by a cPLA$_2$ selective inhibitor or antisense oligonucleotide.[162] In addition, genetic ablation or reduction of cPLA$_2$ protects hAPP mice against Aβ-dependent deficits in learning and memory, behavioral alterations, and premature mortality.[53]

Tau hyperphosphorylation and neurofibrillary tangles are the other pathological hallmark of Alzheimer's disease. All six Tau isoforms that are expressed in the adult human brain are abnormally hyperphosphorylated and form neurofibrillary tangles in AD. *In vivo* PLA$_2$ inhibition decreases the levels of total (nonphosphorylated plus phosphorylated) Tau protein in rat brain.[163] An important mechanism through which both Aβ and tau could be affected is via p25/Cdk5. The latter produces hyperphosphorylated tau and neurofibrillary tangles as well as aberrant amyloid precursor protein processing, and recent evidence indicates increased cPLA$_2$ is essential for triggering p25-mediated inflammatory and neurodegenerative pro-

cesses.[164] Together, results suggest cPLA$_2$ as a therapeutic target for AD.

Studies have been carried out to explore the potential use of botanicals in the treatment of AD. The leaf extract of *Centella asiatica* is used as an alternative medicine for memory improvement in the Indian Ayurvedic system of medicine. Several studies have revealed its effect in ameliorating the cognitive impairment in rat models of AD, and *in vitro* studies reveal that cPLA$_2$ and sPLA$_2$ activities are inhibited *in vitro* by asiaticoside present in the water extract of *Centella asiatica*. This may be a candidate for the treatment of neurodegenerative diseases, because of its pharmacological activity in the brain and low toxicity as demonstrated by its long and popular use.[165]

3.5. Parkinson's Disease. Parkinson's disease (PD) is a neurodegenerative disorder characterized by not only hypokinesia but also mood and cognitive disorders. It involves loss of dopaminergic neurons in the substantia nigra pars compacta and deficits in nigrostriatal dopaminergic transmission, as well as secondary nondopaminergic abnormalities. Increased production of pro-inflammatory cytokines may contribute to the pathogenesis of PD. In unilaterally 6-OHDA and sham lesioned rats, the activity and protein levels of cPLA$_2$ and COX-2 are increased in the caudate putamen, frontal cortex, and remaining brain on the lesioned side, compared to the intact side, or sham controls.[166] Injection of a nonselective PLA$_2$ inhibitor, quinacrine, modulates MPTP or 6-OHDA induced reductions in striatal dopamine.[167] In contrast to cPLA$_2$, decreased iPLA$_2$ is encountered in some cases of PD. PLA2G6 or iPLA$_2$ is reported as the causative gene for early onset PARK14-linked dystonia-parkinsonism, and patients with the PLA2G6 mutation show heterogeneous phenotype such as dystonia-parkinsonism, dementia, and frontotemporal atrophy/hypoperfusion, with or without brain iron accumulation.[168]

Studies have been carried out to explore the use of nutraceuticals for treatment of PD. Treatment of mice with ethyl-eicosapentaenoate (E-EPA) attenuates the MPP(+) induced increase in $n-6$ fatty acids content and striatal dopaminergic turnover and prevents the increase of pro-apoptotic bax and caspase-3 mRNAs.[169] Likewise, feeding mice a 0.8% ethyl-eicosapentaenoate (E-EPA) diet prior to MPTP-P injections reduces hypokinesia induced by MPTP-P and ameliorates procedural memory deficits. Results suggest that omega 3 fatty acids, such as EPA, may be partially protective in the MPTP mouse model of PD.[170]

3.6. Multiple Sclerosis/Experimental Allergic Encephalitis. Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS that results in motor and sensory deficits. Although MS and its animal model, experimental autoimmune encephalomyelitis (EAE), are associated with infiltrating T lymphocytes, the mechanisms underlying the lesions in the CNS are not fully understood. PLA$_2$ is highly expressed in EAE lesions, and inhibition leads to modulation of onset and progression of the disease.[49] Both cPLA$_2$ and iPLA$_2$ are central mediators in MS and EAE. cPLA$_2$ plays a role in onset, and iPLA$_2$, in onset and progression of the disease.[59] The CNS from myelin oligodendrocyte glycoprotein (MOG) immunized mice reveals extensive inflammatory lesions in the cPLA$_2\alpha \pm$ mice, whereas lesions are greatly reduced or absent in cPLA$_2\alpha -/-$ mice.[171] Inhibition of cPLA$_2$ from the onset of clinical EAE reduces duration of EAE relapses.[172] An inhibitor of cPLA$_2$, AACOCF$_3$, reduces clinical symptoms and attenuates the loss of mature, myelin producing, oligodendrocytes and axonal damage in the spinal cord white matter in EAE.[173] Blockade of cPLA$_2\alpha$ with a highly specific

small-molecule inhibitor WAY-196025 during the tissue-damage phase abrogates the clinical features of disease, while therapeutic administration of cPLA$_2\alpha$ inhibitor starting from the peak of disease or during remission completely protects mice from subsequent relapses.[174] sPLA$_2$ may also play a role in MS. Patients show elevations in sPLA$_2$ enzyme activity, and mean levels of sPLA$_2$ increased 6-fold in the urine of patients with active disease and 4-fold for patients in remission, regardless of immunomodulating therapy.[175]

3.7. Pain. PLA$_2$ plays an important role in nociception, in both the PNS and CNS. Skin incision results in activation of keratinocytes and the increase in PLA$_2$ activating protein (PLAA). The latter may be regulated by miR-203, which is strongly downregulated in keratinocytes after incision, and could lead to increased PLAA expression and formation of proinflammatory mediators.[176] The importance of tissue/PNS cPLA$_2$ in nociception is supported by findings of the antinociceptive effect of orally administered cPLA$_2\alpha$ inhibitor, efipladib, which has limited ability to cross the blood−brain barrier.[87] Downstream from cPLA$_2$, treatment with a general LO inhibitor NDGA, a 5-LO inhibitor AA-861, and a 12-LO inhibitor baicalein results in the antinociceptive effect after carrageenan induced inflammation, suggesting the importance of LO in inflammatory pain.[177]

PLA$_2$ activity is increased in the CNS during inflammatory pain, where it may generate lipid mediators that have an effect on neurotransmission along the pain pathway. Lipidomic analyses of the caudal medulla and site of the spinal trigeminal nucleus after facial carrageenan injection shows decreases in phospholipids including phosphatidylethanolamine and phosphatidylinositol species, but increases in lysophospholipids, including lysophosphatidylethanolamine, lysophosphatidylinositol, and lysophosphatidylserine, indicating increased PLA$_2$ activity. Increased sPLA$_2$-III mRNA expression is found in the caudal medulla although there was no difference in sPLA$_2$-III protein expression. Together, results indicate an increase in brain PLA$_2$ enzyme activity after inflammatory orofacial pain, but no change in enzyme protein expression.[178] A study used inhibitors to sPLA$_2$ (12-epi-scalaradial), cPLA$_2$ (AACOCF$_3$), or iPLA$_2$ (BEL) to compare possible contributions of central nervous PLA$_2$ isoforms to the development of allodynia after carrageenan induced inflammation in mice. Intracerebroventricular injection of inhibitors to each of the three PLA$_2$ isoforms reduces responses to von Frey hair stimulation at 8 h and 1 day after facial carrageenan injection, but at 3 days after injection, only the sPLA$_2$ inhibitor has an effect.[50] The antinociceptive effects of PLA$_2$ inhibitors are not simply due to inhibition of AA formation, but also lysophospholipids.[50] Another study showed intrathecal administration of cPLA$_2$ inhibitors MAFP and AACOCF$_3$, but not the iPLA$_2$ inhibitor BEL, dose-dependently prevents thermal hyperalgesia induced by intraplantar carrageenan as well as formalin-induced flinching.[51] Knockdown of spinal cPLA$_2$ by antisense oligonucleotides does not change acute nociception (i.e., paw withdrawal thresholds to acute thermal stimuli and intradermal formalin-induced first phase flinching), but attenuates formalin-induced hyperalgesia (i.e., second phase flinching behavior).[179] As mentioned above, CNS sPLA$_2$ plays a role in spinal nociceptive processing, and intrathecal injection of an inhibitor LY311727 prevents intraplantar carrageenan-induced thermal hyperalgesia and formalin-induced flinching.[65] Together, results point to the important roles of sPLA$_2$ and cPLA$_2$ in nociceptive transmission.

Besides inflammatory pain, PLA$_2$ also plays a role in neuropathic pain. Spinal nerve injury activates cPLA$_2$ in injured dorsal root ganglion neurons and likely contributes to tactile allodynia, where innocuous stimulation elicits pain behavior.[180] Such activation of cPLA$_2$ may involve CaM kinase II, since enzyme inhibition reduces cPLA$_2$ activation and prevents the development and expression of nerve injury-induced tactile allodynia.[181] Nerve injury also results in increased spinal cord cPLA$_2$ and iPLA$_2$ activities, with peaks at 1 h after injury. Both lysophosphatidic acid (LPA) production and neuropathic pain-like behaviors are abolished by intrathecal injection of AACOCF$_3$, or bromoenol lactone, at 1 h after injury.[182] Besides the ascending pain pathway, our preliminary data show that prefrontal cortical iPLA$_2\beta$ activity could be important in the supraspinal *antinociceptive* effect of certain antidepressants (Chew-WS and Ong-WY, unpublished observations).

Intrathecal and systemic injection of a 2-oxoamide cPLA$_2$ inhibitor, AX048, blocks carrageenan induced hyperalgesia. In addition, systemic delivery of AX048 modulates spinally mediated hyperalgesia induced by intrathecal substance P.[109] These findings are significant, as they demonstrate the effectiveness of a systemically administered PLA$_2$ inhibitor on the CNS. The ANXA1 protein also modulates nociceptive processing at the spinal level, by reducing synthesis of PGE$_2$ and modulating cPLA$_2$ and/or COX activity.[183] Treatment with minocycline inhibits LPA-induced microglial activation and neuropathic pain-like behavior,[184] while a recent study shows that (*E*)-4-(3,7-dimethylocta-2,6-dienylamino) phenol (LQFM-015) decreases PLA$_2$ and COX enzyme activity and behavioral responses to carrageenan-induced paw edema and pleurisy.[185] Together, results indicate a close link between anti-inflammatory and antinociceptive activities of compounds.

3.8. Depression. Changes in long-chain polyunsaturated fatty acids (PUFAs) are associated with depression.[186] On the other hand, treatment of mice with certain antidepressants increases iPLA$_2$ activity and endogenous release of PUFAs in brain tissue. PUFAs such as DHA may be metabolized by 15-LO to products such as resolvins that have effects on neuroplasticity. Lipidomic analyses of the prefrontal cortex of mice treated with the antidepressants maprotiline and paroxetine reveal significant decreases in phosphatidylcholine (PC) species (PC36:1, PC38:3, PC40:2p, PC40:6, PC40:5, PC42:7p, PC42:6p, and PC42:5p) but increases in lysophospholipid species (lysoPC16:0, lysoPC18:2, and lysoPC18:0), indicating elevated PLA$_2$ activity and endogenous release of long-chain fatty acids such as DHA.[177] Beneficial effects of maprotiline on depression-like behavior and the above-mentioned changes in lipids are abolished by intracortical injection of antisense oligonucleotide to iPLA$_2$, suggesting a role of the enzyme in antidepressant action.[187]

3.9. Bipolar Disorder. Bipolar disorder is a psychiatric condition characterized by recurrent manic and depressive episodes, without a characteristic neuropathology or clear etiology. Post-mortem samples of frontal cortex from bipolar disorder patients show significantly elevated levels of cPLA$_2$, sPLA$_2$IIA, COX-2, and membrane prostaglandin E synthase.[188] In contrast, mood stabilizers effective in treating mania (lithium, carbamazepine, valproate) or depression (lamotrigine) in bipolar disorder decrease transcription of cPLA$_2$ and COX-2 and decrease AA turnover in brain phospholipids, when administered chronically to rats.[189] A pilot study shows low-dose aspirin, which blocks COX-1 and COX-2, reduces the risk of clinical deterioration in subjects on lithium.[190] Results are consistent

with the AA hypothesis of mood stabilizer action and reports of beneficial effects of *n*−3 PUFA rich- and/or *n*−6 PUFA poor diets in patients with bipolar disorder and migraine.[191]

3.10. Schizophrenia. Schizophrenia is a severe neuropsychiatric disorder associated with cognitive impairment. The condition is associated with changes in brain structure including reduction of gray matter, enlarged ventricles,[192] and loss of dendritic spines from pyramidal neurons in the cortex.[193] Accelerated phospholipid metabolism and reduced dopaminergic activity in the prefrontal cortex are postulated to play a role in schizophrenia.[194] Intracerebroventricular injection of PLA$_2$ in rats results in inhibition of apomorphine-induced locomotion compared to controls, indicating functional inhibition of dopaminergic postsynaptic receptors by PLA$_2$.[195] Moreover, mRNA and protein expression of cPLA$_2$, sPLA$_2$, and COX are elevated, together with increased cytokine and proinflammatory markers in schizophrenic brains (Rao et al., 2013). Brain membranes from the prefrontal cortex of schizophrenic patients demonstrate increased flexibility of fatty acid chains than controls, indicating an increase in PLA$_2$ activity.[196] First-episode schizophrenic patients show increased brain PLA$_2$ activity associated with structural alterations in the left prefrontal cortex and thalamus, while recurrent-episode patients demonstrate widespread associations between PLA$_2$ activity and structural changes in the left hemisphere and cerebellum.[197] The atypical antipsychotic clozapine increases mRNA and protein expression and activity of brain iPLA$_2$, as well as BDNF and of the postsynaptic marker drebrin, while decreasing COX activity and concentration of the AA metabolite, PGE$_2$. This suggests that some of the therapeutic effect of clozapine may involve increasing DHA anti-inflammatory metabolites such as resolvins and decreasing AA derived, proinflammatory mediators.[198]

3.11. Autism. Dysregulated phospholipid metabolism has been proposed as a component of neurodevelopmental disorders such as autistic disorder and attention-deficit/hyperactivity disorder (ADHD).[199] Lysophospholipids released by PLA$_2$ activity are metabolized to platelet activating factor, and recently, platelet-activating factor acetylhydrolase IB subunit alpha (also known as Lis1), an enzyme encoded by the PAFAH1B1 gene, is implicated as an important protein-network interaction node with high-risk autism spectrum disorder genes.[200] PAFAH1B1 is the noncatalytic subunit of an acetylhydrolase complex which inactivates platelet-activating factor by removing the acetyl group at the *sn*-2 position. The protein plays an important role in dendritic filopodia dynamics and spine turnover. Loss of Lis1 results in dysfunction of dynein protein motor and disruption of the actin cytoskeleton through dysregulated RhoGTPases.[200] Results suggest increased PAF activity, leading to alterations in dendritic spine formation and function in autistic disorders, and raise the possibility of PAF inhibitors in management of these conditions.

4. FUTURE DIRECTIONS AND CONCLUSION

Isozymes of PLA$_2$ along with cyclooxygenases have emerged as major players affecting inflammation and oxidative stress in brain tissue. Elucidation of the mechanism of action of the above-mentioned PLA$_2$ inhibitors *in vivo* is an important area of research due to the potential pharmacologic benefits of these compounds as therapeutic agents for the treatment of inflammation and oxidative stress in neurotrauma and neurodegenerative diseases.[201] PLA$_2$ inhibitors have been classified into selective and nonselective types. Selective inhibitors only inhibit PLA$_2$ activity at nanomolar concentrations. In contrast,

nonselective inhibitors inhibit not only PLA$_2$ activity but also other enzymes and receptors.[202] For example, phytochemical based PLA$_2$ inhibitors (curcumin, *Ginkgo biloba*, and *Centella asiatica*) are complex mixtures of bioactive compounds. The levels of bioactive compounds may vary substantially depending upon many factors related to the growth of plants, harvesting, production, and storage conditions. These factors may cause alterations in chemical compositions of dietary phytochemicals resulting in batch variation. This is in contrast to pharmaceuticals that undergo extensive clinical trials in animals and humans prior to FDA approval.

Many chemical inhibitors of PLA$_2$ activity have been described in the literature.[201,203−207] Different mechanisms of action are possible; e.g., an inhibitor can produce alterations in enzymatic activity by perturbing the physicochemical properties of phospholipid bilayers. A PLA$_2$ inhibitor can interact directly with the active site of an isoform, or it can act on an allosteric site on the enzyme to bring about changes in enzymic activity. An inhibitor may also produce a detergent-like structure that can induce nonspecific changes in membrane properties *in vivo* through the interaction of their amphiphilic groups with other membrane components to produce changes in enzymatic activity. As mentioned above, even selective inhibitors of PLA$_2$ have been reported to produce nonspecific effects. For example, the dual cPLA$_2$ and iPLA$_2$ inhibitor methyl arachidonyl fluorophosphonate (MAFP) produces Tau phosphorylation at Ser214, supporting the view that inhibition of both cPLA$_2$ and iPLA$_2$ might influence several biochemical aspects of Tau proteins.[101,163,208] An iPLA$_2$ inhibitor (bromoenol lactone) and cPLA$_2$ inhibitor (palmitoyl trifluoromethyl ketone) retard insulin resistance.[209] Besides inhibiting PLA$_2$ activity, some inhibitors also modulate the expression of cytokines, growth factors, nuclear factor kappa B, and adhesion molecules and, thus, can block endogenous inflammatory reactions and oxidative stress indirectly.

Since the brain contains many isozymes of PLA$_2$, specific PLA$_2$ inhibitors must be designed for testing against individual PLA$_2$ isozymes to establish their physiological and pathological roles in the brain. The design of PLA$_2$ inhibitors should be focused on our rapidly emerging understanding of the role of signal transduction pathways in neurological disorders. At this time, it is quite difficult to predict the potential side effects of the chronic use of cell-permeable, specific or nonselective inhibitors of PLA$_2$. Hence, studies on the availability of specific, nontoxic potent inhibitors with greater blood−brain barrier permeability in animal models of neurodegenerative diseases are urgently needed.

■ AUTHOR INFORMATION

Corresponding Author

*Telephone: (+65) 6516 3662. Fax: (+65) 6778 7643. E-mail: wei_yi_ong@nuhs.edu.sg.

Author Contributions

W.Y.O, T.F., G.K., and A.A.F. wrote the paper.

■ REFERENCES

(1) Phillis, J. W., Horrocks, L. A., and Farooqui, A. A. (2006) Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. *Brain Res. Rev. 52*, 201−243.

(2) Farooqui, A. A. (2012) n−3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation. *Curr. Med. Chem. 19*, 532−543.

(3) Serhan, C. N. (2005) Novel omega-3-derived local mediators in anti-inflammation and resolution. *Pharmacol. Ther. 105*, 7−21.

(4) Farooqui, A. A. (2009) *Hot topics in neural membrane lipidology*; Springer.

(5) Marcheselli, V. L., Hong, S., Lukiw, W. J., Tian, X. H., Gronert, K., Musto, A., Hardy, M., Gimenez, J. M., Chiang, N., Serhan, C. N., and Bazan, N. G. (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. *J. Biol. Chem. 278*, 43807−43817.

(6) Marcheselli, V. L., Mukherjee, P. K., Arita, M., Hong, S., Antony, R., Sheets, K., Winkler, J. W., Petasis, N. A., Serhan, C. N., and Bazan, N. G. (2010) Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. *Prostaglandins Leukot Essent Fatty Acids 82*, 27−34.

(7) Lukiw, W. J., Cui, J. G., Marcheselli, V. L., Bodker, M., Botkjaer, A., Gotlinger, K., Serhan, C. N., and Bazan, N. G. (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. *J. Clin. Invest. 115*, 2774−2783.

(8) Bazan, N. G. (2009) Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photo-receptor cell survival and brain protection. *Prostaglandins Leukot Essent Fatty Acids 81*, 205−211.

(9) Bazan, N. G. (2009) Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. *J. Lipid Res. 50* (Suppl), S400−405.

(10) Adibhatla, R. M., Dempsy, R., and Hatcher, J. F. (2008) Integration of cytokine biology and lipid metabolism in stroke. *Front Biosci. 13*, 1250−1270.

(11) Ong, W. Y., Farooqui, T., and Farooqui, A. A. (2010) Involvement of cytosolic phospholipase A(2), calcium independent phospholipase A(2) and plasmalogen selective phospholipase A(2) in neuro-degenerative and neuropsychiatric conditions. *Curr. Med. Chem. 17*, 2746−2763.

(12) Tucker, D. E., Gijon, M. A., Spencer, D. M., Qiu, Z. H., Gelb, M. H., and Leslie, C. C. (2008) Regulation of cytosolic phospholipase A$_2$alpha by hsp90 and a p54 kinase in okadaic acid-stimulated macrophages. *J. Leukoc. Biol. 84*, 798−806.

(13) Ong, W. Y., Sandhya, T. L., Horrocks, L. A., and Farooqui, A. A. (1999) Distribution of cytoplasmic phospholipase A$_2$ in the normal rat brain. *J. Hirnforsch. 39*, 391−400.

(14) Song, C., Chang, X. J., Bean, K. M., Proia, M. S., Knopf, J. L., and Kriz, R. W. (1999) Molecular characterization of cytosolic phospholipase A$_2$-beta. *J. Biol. Chem. 274*, 17063−17067.

(15) Hefner, Y., Borsch-Haubold, A. G., Murakami, M., Wilde, J. I., Pasquet, S., Schieltz, D., Ghomashchi, F., Yates, J. R., 3rd, Armstrong, C. G., Paterson, A., Cohen, P., Fukunaga, R., Hunter, T., Kudo, I., Watson, S. P., and Gelb, M. H. (2000) Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. *J. Biol. Chem. 275*, 37542−37551.

(16) Geijsen, N., Dijkers, P. F., Lammers, J. J., Koenderman, L., and Coffer, P. J. (2000) Cytokine-mediated cPLA(2) phosphorylation is regulated by multiple MAPK family members. *FEBS Lett. 471*, 83−88.

(17) Lio, Y. C., and Dennis, E. A. (1998) Interfacial activation, lysophospholipase and transacylase activity of group VI Ca^{2+}-independent phospholipase A$_2$. *Biochim. Biophys. Acta 1392*, 320−332.

(18) Jenkins, C. M., Mancuso, D. J., Yan, W., Sims, H. F., Gibson, B., and Gross, R. W. (2004) Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase

A₂ family members possessing triacylglycerol lipase and acylglycerol transacylase activities. *J. Biol. Chem. 279*, 48968−48975.

(19) Jenkins, C. M., Yan, W., Mancuso, D. J., and Gross, R. W. (2006) Highly selective hydrolysis of fatty acyl-CoAs by calcium-independent phospholipase A₂β. Enzyme autoacylation and acyl-CoA-mediated reversal of calmodulin inhibition of phospholipase A₂ activity. *J. Biol. Chem. 281*, 15615−15624.

(20) Ma, Z., Wang, X., Nowatzke, W., Ramanadham, S., and Turk, J. (1999) Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A₂ (iPLA₂) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA₂ gene on chromosome 22q13.1. *J. Biol. Chem. 274*, 9607−9616.

(21) Mancuso, D. J., Jenkins, C. M., and Gross, R. W. (2000) The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A(2). *J. Biol. Chem. 275*, 9937−9945.

(22) Fitzpatrick, J. S., and Baudry, M. (1994) Blockade of long-term depression in neonatal hippocampal slices by a phospholipase A₂ inhibitor. *Brain Res. Dev Brain Res. 78*, 81−86.

(23) Wolf, M. J., Tachibana, H., and Rockman, H. A. (2005) Methods for the detection of altered β-adrenergic receptor signaling pathways in hypertrophied hearts. *Methods Mol. Med. 112*, 353−362.

(24) Allyson, J., Bi, X., Baudry, M., and Massicotte, G. (2012) Maintenance of synaptic stability requires calcium-independent phospholipase A(2) activity. *Neural Plast. 2012*, 569149.

(25) Farooqui, A. A., Ong, W. Y., and Horrocks, L. A. (2006) Inhibitors of brain phospholipase A₂ activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. *Pharmacol Rev. 58*, 591−620.

(26) Thwin, M. M., Ong, W. Y., Fong, C. W., Sato, K., Kodama, K., Farooqui, A. A., and Gopalakrishnakone, P. (2003) Secretory phospholipase A₂ activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum. *Exp. Brain Res. 150*, 427−433.

(27) Farooqui, A. A., Yang, H. C., and Horrocks, L. A. (1995) Plasmalogens, phospholipases A₂ and signal transduction. *Brain Res. Brain Res. Rev. 21*, 152−161.

(28) Yang, H. C., Farooqui, A. A., and Horrocks, L. A. (1996) Plasmalogen-selective phospholipase A₂ and its role in signal transduction. *J. Lipid Mediat. Cell Signal 14*, 9−13.

(29) Farooqui, A. A. (2010) Studies on plasmalogen-selective phospholipase A₂ in brain. *Mol. Neurobiol. 41*, 267−273.

(30) Min, J. H., Wilder, C., Aoki, J., Arai, H., Inoue, K., Paul, L., and Gelb, M. H. (2001) Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme. *Biochemistry 40*, 4539−4549.

(31) Farooqui, A. A., and Horrocks, L. A. (2006) Phospholipase A₂-generated lipid mediators in the brain: the good, the bad, and the ugly. *Neuroscientist 12*, 245−260.

(32) Sun, G. Y., Xu, J., Jensen, M. D., Yu, S., Wood, W. G., Gonzalez, F. A., Simonyi, A., Sun, A. Y., and Weisman, G. A. (2005) Phospholipase A₂ in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists. *Mol. Neurobiol. 31*, 27−41.

(33) Sun, G. Y., Chuang, D. Y., Zong, Y., Jiang, J., Lee, J. C., Gu, Z., and Simonyi, A. (2014) Role of Cytosolic Phospholipase A in Oxidative and Inflammatory Signaling Pathways in Different Cell Types in the Central Nervous System. *Mol. Neurobiol. 50*, 6−14.

(34) Sun, G. Y., Horrocks, L. A., and Farooqui, A. A. (2007) The roles of NADPH oxidase and phospholipases A₂ in oxidative and inflammatory responses in neurodegenerative diseases. *J. Neurochem. 103*, 1−16.

(35) Halliwell, B. (2006) Oxidative stress and neurodegeneration: where are we now? *J. Neurochem. 97*, 1634−1658.

(36) Chiurchiu, V., and Maccarrone, M. (2011) Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. *Antioxid. Redox Signal. 15*, 2605−2641.

(37) von Bernhardi, R., and Eugenin, J. (2012) Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. *Antioxid. Redox Signal. 16*, 974−1031.

(38) Farooqui, A. A. (2011) *Lipid mediators and their metabolism in the brain*; Springer.

(39) Murakami, M., Taketomi, Y., Miki, Y., Sato, H., Hirabayashi, T., and Yamamoto, K. (2011) Recent progress in phospholipase A(2) research: from cells to animals to humans. *Prog. Lipid Res. 50*, 152−192.

(40) Hermann, P. M., Park, D., Beaulieu, E., and Wildering, W. C. (2013) Evidence for inflammation-mediated memory dysfunction in gastropods: putative PLA₂ and COX inhibitors abolish long-term memory failure induced by systemic immune challenges. *BMC Neurosci. 14*, 83.

(41) Sanchez-Mejia, R. O., and Mucke, L. (2010) Phospholipase A₂ and arachidonic acid in Alzheimer's disease. *Biochim. Biophys. Acta 1801*, 784−790.

(42) Sun, G. Y., Xu, J., Jensen, M. D., and Simonyi, A. (2004) Phospholipase A₂ in the central nervous system: implications for neurodegenerative diseases. *J. Lipid Res. 45*, 205−213.

(43) Trimble, L. A., Street, I. P., Perrier, H., Tremblay, N. M., Weech, P. K., and Bernstein, M. A. (1993) NMR structural studies of the tight complex between a trifluoromethyl ketone inhibitor and the 85-kDa human phospholipase A₂. *Biochemistry 32*, 12560−12565.

(44) Street, I. P., Lin, H. K., Laliberte, F., Ghomashchi, F., Wang, Z., Perrier, H., Tremblay, N. M., Huang, Z., Weech, P. K., and Gelb, M. H. (1993) Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A₂. *Biochemistry 32*, 5935−5940.

(45) Ghomashchi, F., Loo, R., Balsinde, J., Bartoli, F., Apitz-Castro, R., Clark, J. D., Dennis, E. A., and Gelb, M. H. (1999) Trifluoromethyl ketones and methyl fluorophosphonates as inhibitors of group IV and VI phospholipases A(2): structure-function studies with vesicle, micelle, and membrane assays. *Biochim. Biophys. Acta 1420*, 45−56.

(46) Conde-Frieboes, K., Reynolds, L. J., Lio, Y.-C., Hale, M. R., Wasserman, H. H., and Dennis, E. A. (1996) Activated ketones as inhibitors of intracellular Ca²⁺-dependent and Ca²⁺-independent phospholipase A₂. *J. Am. Chem. Soc. 118*, 5519−5525.

(47) Ackermann, E. J., Conde-Frieboes, K., and Dennis, E. A. (1995) Inhibition of macrophage Ca(2+)-independent phospholipase A₂ by bromoenol lactone and trifluoromethyl ketones. *J. Biol. Chem. 270*, 445−450.

(48) Leis, H. J., and Windischhofer, W. (2008) Inhibition of cyclooxygenases 1 and 2 by the phospholipase-blocker, arachidonyl trifluoromethyl ketone. *Br. J. Pharmacol. 155*, 731−737.

(49) Kalyvas, A., and David, S. (2004) Cytosolic phospholipase A₂ plays a key role in the pathogenesis of multiple sclerosis-like disease. *Neuron 41*, 323−335.

(50) Yeo, J. F., Ong, W. Y., Ling, S. F., and Farooqui, A. A. (2004) Intracerebroventricular injection of phospholipases A₂ inhibitors modulates allodynia after facial carrageenan injection in mice. *Pain 112*, 148−155.

(51) Lucas, K. K., Svensson, C. I., Hua, X. Y., Yaksh, T. L., and Dennis, E. A. (2005) Spinal phospholipase A₂ in inflammatory hyperalgesia: role of group IVA cPLA₂. *Br. J. Pharmacol. 144*, 940−952.

(52) Bate, C., Reid, S., and Williams, A. (2004) Phospholipase A₂ inhibitors or platelet-activating factor antagonists prevent prion replication. *J. Biol. Chem. 279*, 36405−36411.

(53) Sanchez-Mejia, R. O., Newman, J. W., Toh, S., Yu, G. Q., Zhou, Y., Halabisky, B., Cisse, M., Scearce-Levie, K., Cheng, I. H., Gan, L., Palop, J. J., Bonventre, J. V., and Mucke, L. (2008) Phospholipase A₂ reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. *Nat. Neurosci. 11*, 1311−1318.

(54) Baskakis, C., Magrioti, V., Cotton, N., Stephens, D., Constantinou-Kokotou, V., Dennis, E. A., and Kokotos, G. (2008) Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A₂ enzymes. *J. Med. Chem. 51*, 8027−8037.

(55) Kokotos, G., Hsu, Y. H., Burke, J. E., Baskakis, C., Kokotos, C. G., Magrioti, V., and Dennis, E. A. (2010) Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A₂. *J. Med. Chem. 53*, 3602−3610.

(56) Magrioti, V., Nikolaou, A., Smyrniotou, A., Shah, I., Constantinou-Kokotou, V., Dennis, E. A., and Kokotos, G. (2013) New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2. *Bioorg. Med. Chem.* 21, 5823–5829.

(57) Hsu, Y. H., Bucher, D., Cao, J., Li, S., Yang, S. W., Kokotos, G., Woods, V. L., Jr., McCammon, J. A., and Dennis, E. A. (2013) Fluoroketone inhibition of Ca(2+)-independent phospholipase A2 through binding pocket association defined by hydrogen/deuterium exchange and molecular dynamics. *J. Am. Chem. Soc.* 135, 1330–1337.

(58) Lopez-Vales, R., Navarro, X., Shimizu, T., Baskakis, C., Kokotos, G., Constantinou-Kokotou, V., Stephens, D., Dennis, E. A., and David, S. (2008) Intracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury. *Brain* 131, 2620–2631.

(59) Kalyvas, A., Baskakis, C., Magrioti, V., Constantinou-Kokotou, V., Stephens, D., Lopez-Vales, R., Lu, J. Q., Yong, V. W., Dennis, E. A., Kokotos, G., and David, S. (2009) Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. *Brain* 132, 1221–1235.

(60) Paliege, A., Roeschel, T., Neymeyer, H., Seidel, S., Kahl, T., Daigeler, A. L., Mutig, K., Mrowka, R., Ferreri, N. R., Wilson, B. S., Himmerkus, N., Bleich, M., and Bachmann, S. (2012) Group VIA phospholipase A2 is a target for vasopressin signaling in the thick ascending limb. *Am. J. Physiol. Renal. Physiol.* 302, F865–874.

(61) Lei, X., Barbour, S. E., and Ramanadham, S. (2010) Group VIA Ca^{2+}-independent phospholipase A2 (iPLA2β) and its role in beta-cell programmed cell death. *Biochimie* 92, 627–637.

(62) Ali, T., Kokotos, G., Magrioti, V., Bone, R. N., Mobley, J. A., Hancock, W., and Ramanadham, S. (2013) Characterization of FKGK18 as inhibitor of group VIA Ca^{2+}-independent phospholipase A2 (iPLA2β): candidate drug for preventing beta-cell apoptosis and diabetes. *PLoS One* 8, e71748.

(63) Gil-de-Gomez, L., Astudillo, A. M., Guijas, C., Magrioti, V., Kokotos, G., Balboa, M. A., and Balsinde, J. (2014) Cytosolic group IVA and calcium-independent group VIA phospholipase A2s act on distinct phospholipid pools in zymosan-stimulated mouse peritoneal macrophages. *J. Immunol.* 192, 752–762.

(64) Lio, Y. C., Reynolds, L. J., Balsinde, J., and Dennis, E. A. (1996) Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. *Biochim. Biophys. Acta* 1302, 55–60.

(65) Svensson, C. I., Lucas, K. K., Hua, X. Y., Powell, H. C., Dennis, E. A., and Yaksh, T. L. (2005) Spinal phospholipase A2 in inflammatory hyperalgesia: role of the small, secretory phospholipase A2. *Neuroscience* 133, 543–553.

(66) Balsinde, J., Bianco, I. D., Ackermann, E. J., Conde-Frieboes, K., and Dennis, E. A. (1995) Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. *Proc. Natl. Acad. Sci. U.S.A.* 92, 8527–8531.

(67) Hazen, S. L., Zupan, L. A., Weiss, R. H., Getman, D. P., and Gross, R. W. (1991) Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A2. Mechanism-based discrimination between calcium-dependent and -independent phospholipases A2. *J. Biol. Chem.* 266, 7227–7232.

(68) Jenkins, C. M., Han, X., Mancuso, D. J., and Gross, R. W. (2002) Identification of calcium-independent phospholipase A2 (iPLA2)β, and not iPLA2γ, as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2s. *J. Biol. Chem.* 277, 32807–32814.

(69) Saavedra, G., Zhang, W., Peterson, B., and Cummings, B. S. (2006) Differential roles for cytosolic and microsomal Ca^{2+}-independent phospholipase A2 in cell growth and maintenance of phospholipids. *J. Pharmacol. Exp. Ther.* 318, 1211–1219.

(70) Kinsey, G. R., Cummings, B. S., Beckett, C. S., Saavedra, G., Zhang, W., McHowat, J., and Schnellmann, R. G. (2005) Identification

and distribution of endoplasmic reticulum iPLA2. *Biochem. Biophys. Res. Commun.* 327, 287–293.

(71) Song, H., Ramanadham, S., Bao, S., Hsu, F. F., and Turk, J. (2006) A bromoenol lactone suicide substrate inactivates group VIA phospholipase A2 by generating a diffusible bromomethyl keto acid that alkylates cysteine thiols. *Biochemistry* 45, 1061–1073.

(72) Jenkins, C. M., Yang, J., and Gross, R. W. (2013) Mechanism-based inhibition of iPLA2β demonstrates a highly reactive cysteine residue (C651) that interacts with the active site: mass spectrometric elucidation of the mechanisms underlying inhibition. *Biochemistry* 52, 4250–4263.

(73) Balsinde, J., and Dennis, E. A. (1996) Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages. *J. Biol. Chem.* 271, 31937–31941.

(74) Akiba, S., Hayama, M., and Sato, T. (1998) Inhibition of Ca^{2+}-independent phospholipase A2 by bromoenol lactone attenuates prostaglandin generation induced by interleukin-1 β and dibutyryl cAMP in rat mesangial cells. *FEBS Lett.* 437, 225–228.

(75) Sanchez, T., and Moreno, J. J. (2001) The effect of high molecular phospholipase A2 inhibitors on 3T6 fibroblast proliferation. *Biochem. Pharmacol.* 61, 811–816.

(76) St-Gelais, F., Menard, C., Congar, P., Trudeau, L. E., and Massicotte, G. (2004) Postsynaptic injection of calcium-independent phospholipase A2 inhibitors selectively increases AMPA receptor-mediated synaptic transmission. *Hippocampus* 14, 319–325.

(77) Sun, B., Zhang, X., Talathi, S., and Cummings, B. S. (2008) Inhibition of Ca^{2+}-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms. *J. Pharmacol. Exp. Ther.* 326, 59–68.

(78) Sun, B., Zhang, X., Yonz, C., and Cummings, B. S. (2010) Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells. *Biochem. Pharmacol.* 79, 1727–1735.

(79) Schevitz, R. W., Bach, N. J., Carlson, D. G., Chirgadze, N. Y., Clawson, D. K., Dillard, R. D., Draheim, S. E., Hartley, L. W., Jones, N. D., Mihelich, E. D., et al. (1995) Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. *Nat. Struct. Biol.* 2, 458–465.

(80) Draheim, S. E., Bach, N. J., Dillard, R. D., Berry, D. R., Carlson, D. G., Chirgadze, N. Y., Clawson, D. K., Hartley, L. W., Johnson, L. M., Jones, N. D., McKinney, E. R., Mihelich, E. D., Olkowski, J. L., Schevitz, R. W., Smith, A. C., Snyder, D. W., Sommers, C. D., and Wery, J. P. (1996) Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides. *J. Med. Chem.* 39, 5159–5175.

(81) Snyder, D. W., Bach, N. J., Dillard, R. D., Draheim, S. E., Carlson, D. G., Fox, N., Roehm, N. W., Armstrong, C. T., Chang, C. H., Hartley, L. W., Johnson, L. M., Roman, C. R., Smith, A. C., Song, M., and Fleisch, J. H. (1999) Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. *J. Pharmacol. Exp. Ther.* 288, 1117–1124.

(82) Dillard, R. D., Bach, N. J., Draheim, S. E., Berry, D. R., Carlson, D. G., Chirgadze, N. Y., Clawson, D. K., Hartley, L. W., Johnson, L. M., Jones, N. D., McKinney, E. R., Mihelich, E. D., Olkowski, J. L., Schevitz, R. W., Smith, A. C., Snyder, D. W., Sommers, C. D., and Wery, J. P. (1996) Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality. *J. Med. Chem.* 39, 5137–5158.

(83) Anthera Pharmaceuticals (2008) Treatment of Cardiovascular Disease and Dyslipidemia Using Secretory Phospholipase A2 (sPLA2) Inhibitors and sPLA2 Inhibitor Combination Therapies.

(84) Anthera Pharmaceuticals (2010) Treatment of Major Adverse Cardiac Events and Acute Coronary Syndrome Using Secretory Phospholipase A2 (sPLA2) Inhibitor or sPLA2 Inhibitor Combination Therapies.

(85) Lee, K. L., Foley, M. A., Chen, L., Behnke, M. L., Lovering, F. E., Kirincich, S. J., Wang, W., Shim, J., Tam, S., Shen, M. W., Khor, S., Xu, X., Goodwin, D. G., Ramarao, M. K., Nickerson-Nutter, C., Donahue, F.,

Ku, M. S., Clark, J. D., and McKew, J. C. (2007) Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A₂alpha. *J. Med. Chem. 50*, 1380−1400.

(86) McKew, J. C., Lee, K. L., Shen, M. W., Thakker, P., Foley, M. A., Behnke, M. L., Hu, B., Sum, F. W., Tam, S., Hu, Y., Chen, L., Kirincich, S. J., Michalak, R., Thomason, J., Ipek, M., Wu, K., Wooder, L., Ramarao, M. K., Murphy, E. A., Goodwin, D. G., Albert, L., Xu, X., Donahue, F., Ku, M. S., Keith, J., Nickerson-Nutter, C. L., Abraham, W. M., Williams, C., Hegen, M., and Clark, J. D. (2008) Indole cytosolic phospholipase A₂ alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1*H*-indol-3-yl]propyl}benzoic acid, efipladib. *J. Med. Chem. 51*, 3388−3413.

(87) Nickerson-Nutter, C. L., Goodwin, D., Shen, M. W., Damphousse, C., Duan, W., Samad, T. A., McKew, J. C., Lee, K. L., Zaleska, M. M., Mollova, N., and Clark, J. D. (2011) The cPLA₂α inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid. *Neuropharmacology 60*, 633−641.

(88) Seno, K., Okuno, T., Nishi, K., Murakami, Y., Watanabe, F., Matsuura, T., Wada, M., Fujii, Y., Yamada, M., Ogawa, T., Okada, T., Hashizume, H., Kii, M., Hara, S., Hagishita, S., Nakamoto, S., Yamada, K., Chikazawa, Y., Ueno, M., Teshirogi, I., Ono, T., and Ohtani, M. (2000) Pyrrolidine inhibitors of human cytosolic phospholipase A(2). *J. Med. Chem. 43*, 1041−1044.

(89) Ghomashchi, F., Stewart, A., Hefner, Y., Ramanadham, S., Turk, J., Leslie, C. C., and Gelb, M. H. (2001) A pyrrolidine-based specific inhibitor of cytosolic phospholipase A(2)α blocks arachidonic acid release in a variety of mammalian cells. *Biochim. Biophys. Acta 1513*, 160−166.

(90) Seno, K., Okuno, T., Nishi, K., Murakami, Y., Yamada, K., Nakamoto, S., and Ono, T. (2001) Pyrrolidine inhibitors of human cytosolic phospholipase A₂. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'. *Bioorg. Med. Chem. Lett. 11*, 587−590.

(91) Ono, T., Yamada, K., Chikazawa, Y., Ueno, M., Nakamoto, S., Okuno, T., and Seno, K. (2002) Characterization of a novel inhibitor of cytosolic phospholipase A₂α, pyrrophenone. *Biochem. J. 363*, 727−735.

(92) Tai, N., Kuwabara, K., Kobayashi, M., Yamada, K., Ono, T., Seno, K., Gahara, Y., Ishizaki, J., and Hori, Y. (2010) Cytosolic phospholipase A₂ alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model. *Inflamm. Res. 59*, 53−62.

(93) Beaton, H. G., Bennion, C., Connolly, S., Cook, A. R., Gensmantel, N. P., Hallam, C., Hardy, K., Hitchin, B., Jackson, C. G., and Robinson, D. H. (1994) Discovery of new non-phospholipid inhibitors of the secretory phospholipases A₂. *J. Med. Chem. 37*, 557−559.

(94) Cha, S. S., Lee, D., Adams, J., Kurdyla, J. T., Jones, C. S., Marshall, L. A., Bolognese, B., Abdel-Meguid, S. S., and Oh, B. H. (1996) High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A₂ and a highly potent inhibitor (FPL67047XX). *J. Med. Chem. 39*, 3878−3881.

(95) Hansford, K. A., Reid, R. C., Clark, C. I., Tyndall, J. D., Whitehouse, M. W., Guthrie, T., McGeary, R. P., Schafer, K., Martin, J. L., and Fairlie, D. P. (2003) D-Tyrosine as a chiral precursor to potent inhibitors of human nonpancreatic secretory phospholipase A₂ (IIa) with antiinflammatory activity. *ChemBioChem 4*, 181−185.

(96) Arumugam, T. V., Arnold, N., Proctor, L. M., Newman, M., Reid, R. C., Hansford, K. A., Fairlie, D. P., Shiels, I. A., and Taylor, S. M. (2003) Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1, and COX-2 selective inhibitors, and an LTC4 receptor antagonist. *Br. J. Pharmacol. 140*, 71−80.

(97) Woodruff, T. M., Arumugam, T. V., Shiels, I. A., Newman, M. L., Ross, P. A., Reid, R. C., Fairlie, D. P., and Taylor, S. M. (2005) A potent and selective inhibitor of group IIa secretory phospholipase A₂ protects rats from TNBS-induced colitis. *Int. Immunopharmacol. 5*, 883−892.

(98) Levick, S., Loch, D., Rolfe, B., Reid, R. C., Fairlie, D. P., Taylor, S. M., and Brown, L. (2006) Antifibrotic activity of an inhibitor of group

IIA secretory phospholipase A₂ in young spontaneously hypertensive rats. *J. Immunol. 176*, 7000−7007.

(99) Gregory, L. S., Kelly, W. L., Reid, R. C., Fairlie, D. P., and Forwood, M. R. (2006) Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A₂ preserve bone architecture following ovariectomy in adult rats. *Bone 39*, 134−142.

(100) Antonopoulou, G., Barbayianni, E., Magrioti, V., Cotton, N., Stephens, D., Constantinou-Kokotou, V., Dennis, E. A., and Kokotos, G. (2008) Structure−activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. *Bioorg. Med. Chem. 16*, 10257−10269.

(101) Lopez-Vales, R., Ghasemlou, N., Redensek, A., Kerr, B. J., Barbayianni, E., Antonopoulou, G., Baskakis, C., Rathore, K. I., Constantinou-Kokotou, V., Stephens, D., Shimizu, T., Dennis, E. A., Kokotos, G., and David, S. (2011) Phospholipase A₂ superfamily members play divergent roles after spinal cord injury. *FASEB J. 25*, 4240−4252.

(102) Kokotos, G., Kotsovolou, S., Six, D. A., Constantinou-Kokotou, V., Beltzner, C. C., and Dennis, E. A. (2002) Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2). *J. Med. Chem. 45*, 2891−2893.

(103) Kokotos, G., Six, D. A., Loukas, V., Smith, T., Constantinou-Kokotou, V., Hadjipavlou-Litina, D., Kotsovolou, S., Chiou, A., Beltzner, C. C., and Dennis, E. A. (2004) Inhibition of group IVA cytosolic phospholipase A₂ by novel 2-oxoamides in vitro, in cells, and in vivo. *J. Med. Chem. 47*, 3615−3628.

(104) Constantinou-Kokotou, V., Peristeraki, A., Kokotos, C. G., Six, D. A., and Dennis, E. A. (2005) Synthesis and activity of 2-oxoamides containing long chain beta-amino acids. *J. Pept. Sci. 11*, 431−435.

(105) Stephens, D., Barbayianni, E., Constantinou-Kokotou, V., Peristeraki, A., Six, D. A., Cooper, J., Harkewicz, R., Deems, R. A., Dennis, E. A., and Kokotos, G. (2006) Differential inhibition of group IVA and group VIA phospholipases A₂ by 2-oxoamides. *J. Med. Chem. 49*, 2821−2828.

(106) Six, D. A., Barbayianni, E., Loukas, V., Constantinou-Kokotou, V., Hadjipavlou-Litina, D., Stephens, D., Wong, A. C., Magrioti, V., Moutevelis-Minakakis, P., Baker, S. F., Dennis, E. A., and Kokotos, G. (2007) Structure−activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A₂ and group V secreted phospholipase A2. *J. Med. Chem. 50*, 4222−4235.

(107) Burke, J. E., Babakhani, A., Gorfe, A. A., Kokotos, G., Li, S., Woods, V. L., Jr., McCammon, J. A., and Dennis, E. A. (2009) Location of inhibitors bound to group IVA phospholipase A₂ determined by molecular dynamics and deuterium exchange mass spectrometry. *J. Am. Chem. Soc. 131*, 8083−8091.

(108) Mouchlis, V. D., Magrioti, V., Barbayianni, E., Cermak, N., Oslund, R. C., Mavromoustakos, T. M., Gelb, M. H., and Kokotos, G. (2011) Inhibition of secreted phospholipases A(2) by 2-oxoamides based on α-amino acids: Synthesis, in vitro evaluation and molecular docking calculations. *Bioorg. Med. Chem. 19*, 735−743.

(109) Yaksh, T. L., Kokotos, G., Svensson, C. I., Stephens, D., Kokotos, C. G., Fitzsimmons, B., Hadjipavlou-Litina, D., Hua, X. Y., and Dennis, E. A. (2006) Systemic and intrathecal effects of a novel series of phospholipase A₂ inhibitors on hyperalgesia and spinal prostaglandin E2 release. *J. Pharmacol. Exp. Ther. 316*, 466−475.

(110) Yang, D., Ji, H. F., Zhang, X. M., Yue, H., Lin, L., Ma, Y. Y., Huang, X. N., Fu, J., and Wang, W. Z. (2014) Protective effect of cytosolic phospholipase A₂ inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis. *Mediators Inflamm. 2014*, 890139.

(111) Connolly, S., Bennion, C., Botterell, S., Croshaw, P. J., Hallam, C., Hardy, K., Hartopp, P., Jackson, C. G., King, S. J., Lawrence, L., Mete, A., Murray, D., Robinson, D. H., Smith, G. M., Stein, L., Walters, I., Wells, E., and Withnall, W. J. (2002) Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A(2) based on a 1,3-disubstituted propan-2-one skeleton. *J. Med. Chem. 45*, 1348−1362.

(112) Ludwig, J., Bovens, S., Brauch, C., Elfringhoff, A. S., and Lehr, M. (2006) Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors

of human cytosolic phospholipase A$_2$alpha. *J. Med. Chem.* 49, 2611−2620.

(113) Hess, M., Schulze Elfringhoff, A., and Lehr, M. (2007) 1-(5-Carboxy- and 5-carbamoylindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A$_2\alpha$: bioisosteric replacement of the carboxylic acid and carboxamide moiety. *Bioorg. Med. Chem.* 15, 2883−2891.

(114) Fritsche, A., Elfringhoff, A. S., Fabian, J., and Lehr, M. (2008) 1-(2-Carboxyindol-5-yloxy)propan-2-ones as inhibitors of human cytosolic phospholipase A$_2\alpha$: synthesis, biological activity, metabolic stability, and solubility. *Bioorg. Med. Chem.* 16, 3489−3500.

(115) Forster, L., Ludwig, J., Kaptur, M., Bovens, S., Elfringhoff, A. S., Holtfrerich, A., and Lehr, M. (2010) 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. *Bioorg. Med. Chem.* 18, 945−952.

(116) Drews, A., Bovens, S., Roebrock, K., Sunderkotter, C., Reinhardt, D., Schafers, M., van der Velde, A., Schulze Elfringhoff, A., Fabian, J., and Lehr, M. (2010) 1-(5-Carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A(2)α with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity. *J. Med. Chem.* 53, 5165−5178.

(117) Lombardo, D., and Dennis, E. A. (1985) Cobra venom phospholipase A$_2$ inhibition by manoalide. A novel type of phospholipase inhibitor. *J. Biol. Chem.* 260, 7234−7240.

(118) Haefner, B. (2003) Drugs from the deep: marine natural products as drug candidates. *Drug Discov. Today* 8, 536−544.

(119) Monti, M. C., Casapullo, A., Cavasotto, C. N., Napolitano, A., and Riccio, R. (2007) Scalaradial, a dialdehyde-containing marine metabolite that causes an unexpected noncovalent PLA$_2$ Inactivation. *ChemBioChem* 8, 1585−1591.

(120) Marshall, L. A., Winkler, J. D., Griswold, D. E., Bolognese, B., Roshak, A., Sung, C. M., Webb, E. F., and Jacobs, R. (1994) Effects of scalaradial, a type II phospholipase A$_2$ inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation. *J. Pharmacol. Exp. Ther.* 268, 709−717.

(121) Valenzuela, C. F., Kerr, J. A., and Johnson, D. A. (1992) Quinacrine binds to the lipid-protein interface of the Torpedo acetylcholine receptor: a fluorescence study. *J. Biol. Chem.* 267, 8238−8244.

(122) Mustonen, P., Lehtonen, J. Y., and Kinnunen, P. K. (1998) Binding of quinacrine to acidic phospholipids and pancreatic phospholipase A$_2$. Effects on the catalytic activity of the enzyme. *Biochemistry* 37, 12051−12057.

(123) Lister, M. D., Glaser, K. B., Ulevitch, R. J., and Dennis, E. A. (1989) Inhibition studies on the membrane-associated phospholipase A$_2$ in vitro and prostaglandin E$_2$ production in vivo of the macrophage-like P388D1 cell. Effects of manoalide, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacyl bromide. *J. Biol. Chem.* 264, 8520−8528.

(124) Cunningham, T. J., Maciejewski, J., and Yao, L. (2006) Inhibition of secreted phospholipase A$_2$ by neuron survival and anti-inflammatory peptide CHEC-9. *J. Neuroinflammation* 3, 25.

(125) Wang, Q., Sun, A. Y., Pardeike, J., Muller, R. H., Simonyi, A., and Sun, G. Y. (2009) Neuroprotective effects of a nanocrystal formulation of sPLA(2) inhibitor PX-18 in cerebral ischemia/reperfusion in gerbils. *Brain Res.* 1285, 188−195.

(126) Kuribayashi, Y., Yoshida, K., Sakaue, T., and Okumura, A. (1992) In vitro studies on the influence of L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6yl-hydrogen phosphate] potassium salt on lipid peroxidation and phospholipase A$_2$ activity. *Arzneimittelforschung* 42, 1072−1074.

(127) Farooqui, A. A.; Ong, W.-Y.; Horrocks, L. A. (2008) *Neurochemical aspects of excitotoxicity*; Springer.

(128) Dumuis, A., Sebben, M., Haynes, L., Pin, J. P., and Bockaert, J. (1988) NMDA receptors activate the arachidonic acid cascade system in striatal neurons. *Nature* 336, 68−70.

(129) Wei, S., Ong, W. Y., Thwin, M. M., Fong, C. W., Farooqui, A. A., Gopalakrishnakone, P., and Hong, W. (2003) Group IIA secretory phospholipase A$_2$ stimulates exocytosis and neurotransmitter release in

pheochromocytoma-12 cells and cultured rat hippocampal neurons. *Neuroscience* 121, 891−898.

(130) Phillis, J. W., and O'Regan, M. H. (1996) Mechanisms of glutamate and aspartate release in the ischemic rat cerebral cortex. *Brain Res.* 730, 150−164.

(131) Than, A., Tan, Y., Ong, W. Y., Farooqui, A. A., and Chen, P. (2012) Kainate receptors mediate regulated exocytosis of secretory phospholipase A(2) in SH-SY5Y neuroblastoma cells. *Neurosignals* 20, 72−85.

(132) Kim, D. K., Rordorf, G., Nemenoff, R. A., Koroshetz, W. J., and Bonventre, J. V. (1995) Glutamate stably enhances the activity of two cytosolic forms of phospholipase A$_2$ in brain cortical cultures. *Biochem. J.* 310 (Pt 1), 83−90.

(133) Bonventre, J. V. (1997) Roles of phospholipases A$_2$ in brain cell and tissue injury associated with ischemia and excitotoxicity. *J. Lipid Mediat. Cell Signal.* 16, 199−208.

(134) Sandhya, T. L., Ong, W. Y., Horrocks, L. A., and Farooqui, A. A. (1998) A light and electron microscopic study of cytoplasmic phospholipase A$_2$ and cyclooxygenase-2 in the hippocampus after kainate lesions. *Brain Res.* 788, 223−231.

(135) Ong, W. Y., Lu, X. R., Hu, C. Y., and Halliwell, B. (2000) Distribution of hydroxynonenal-modified proteins in the kainate-lesioned rat hippocampus: evidence that hydroxynonenal formation precedes neuronal cell death. *Free Radic. Biol. Med.* 28, 1214−1221.

(136) Farooqui, A. A., Ong, W. Y., and Horrocks, L. A. (2004) Neuroprotection abilities of cytosolic phospholipase A$_2$ inhibitors in kainic acid-induced neurodegeneration. *Curr. Drug Targets Cardiovasc. Haematol. Disord.* 4, 85−96.

(137) Ueda, Y., Kitamoto, A., Willmore, L. J., and Kojima, T. (2011) Hippocampal gene network analysis in an experimental model of posttraumatic epilepsy. *Neurochem. Res.* 36, 1323−1328.

(138) Chiricozzi, E., Fernandez-Fernandez, S., Nardicchi, V., Almeida, A., Bolanos, J. P., and Goracci, G. (2010) Group IIA secretory phospholipase A$_2$ (GIIA) mediates apoptotic death during NMDA receptor activation in rat primary cortical neurons. *J. Neurochem.* 112, 1574−1583.

(139) Zhao, Z., Liu, N., Huang, J., Lu, P. H., and Xu, X. M. (2011) Inhibition of cPLA$_2$ activation by Ginkgo biloba extract protects spinal cord neurons from glutamate excitotoxicity and oxidative stress-induced cell death. *J. Neurochem.* 116, 1057−1065.

(140) Barbosa, N. R., Pittella, F., and Gattaz, W. F. (2008) Centella asiatica water extract inhibits iPLA$_2$ and cPLA$_2$ activities in rat cerebellum. *Phytomedicine* 15, 896−900.

(141) Lu, X. R., Ong, W. Y., and Halliwell, B. (2001) The phospholipase A$_2$ inhibitor quinacrine prevents increased immunor-eactivity to cytoplasmic phospholipase A$_2$ (cPLA$_2$) and hydroxynonenal (HNE) in neurons of the lateral septum following fimbria-fornix transection. *Exp Brain Res.* 138, 500−508.

(142) Sharma, S., Ying, Z., and Gomez-Pinilla, F. (2010) A pyrazole curcumin derivative restores membrane homeostasis disrupted after brain trauma. *Exp. Neurol.* 226, 191−199.

(143) Cunningham, T. J., Souayah, N., Jameson, B., Mitchell, J., and Yao, L. (2004) Systemic treatment of cerebral cortex lesions in rats with a new secreted phospholipase A$_2$ inhibitor. *J. Neurotrauma* 21, 1683−1691.

(144) Liu, N. K., and Xu, X. M. (2010) Phospholipase A$_2$ and its molecular mechanism after spinal cord injury. *Mol. Neurobiol.* 41, 197−205.

(145) Titsworth, W. L., Cheng, X., Ke, Y., Deng, L., Burckardt, K. A., Pendleton, C., Liu, N. K., Shao, H., Cao, Q. L., and Xu, X. M. (2009) Differential expression of sPLA$_2$ following spinal cord injury and a functional role for sPLA$_2$-IIA in mediating oligodendrocyte death. *Glia* 57, 1521−1537.

(146) Liu, N. K., Deng, L. X., Zhang, Y. P., Lu, Q. B., Wang, X. F., Hu, J. G., Oakes, E., Bonventre, J. V., Shields, C. B., and Xu, X. M. (2014) Cytosolic phospholipase A$_2$ protein as a novel therapeutic target for spinal cord injury. *Ann. Neurol.* 75, 644−658.

(147) Block, F., Kunkel, M., and Sontag, K. H. (1995) Posttreatment with EPC-K1, an inhibitor of lipid peroxidation and of phospholipase A$_2$

activity, reduces functional deficits after global ischemia in rats. *Brain Res. Bull.* 36, 257−260.

(148) Estevez, A. Y., and Phillis, J. W. (1997) The phospholipase A2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion. *Brain Res.* 752, 203−208.

(149) Nito, C., Kamada, H., Endo, H., Niizuma, K., Myer, D. J., and Chan, P. H. (2008) Role of the p38 mitogen-activated protein kinase/cytosolic phospholipase A₂ signaling pathway in blood−brain barrier disruption after focal cerebral ischemia and reperfusion. *J. Cereb. Blood Flow Metab.* 28, 1686−1696.

(150) Kishimoto, K., Li, R. C., Zhang, J., Klaus, J. A., Kibler, K. K., Dore, S., Koehler, R. C., and Sapirstein, A. (2010) Cytosolic phospholipase A₂ alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice. *J. Neuroinflammation* 7, 42.

(151) Zhang, J., Barasch, N., Li, R. C., and Sapirstein, A. (2012) Inhibition of cytosolic phospholipase A(2) α protects against focal ischemic brain damage in mice. *Brain Res.* 1471, 129−137.

(152) Cui, L., Zhang, X., Yang, R., Wang, L., Liu, L., Li, M., and Du, W. (2010) Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability. *Brain Res.* 1325, 164−173.

(153) Gabryel, B., Bielecka, A., Stolecka, A., Bernacki, J., and Langfort, J. (2010) Cytosolic phospholipase A(2) inhibition is involved in the protective effect of nortriptyline in primary astrocyte cultures exposed to combined oxygen-glucose deprivation. *Pharmacol. Rep.* 62, 814−826.

(154) Torregrosa, G., Perez-Asensio, F. J., Burguete, M. C., Castello-Ruiz, M., Salom, J. B., and Alborch, E. (2007) Chronic intracerebroventricular delivery of the secretory phospholipase A₂ inhibitor, 12-epi-scalaradial, does not improve outcome after focal cerebral ischemia-reperfusion in rats. *Exp. Brain Res.* 176, 248−259.

(155) Hoda, M. N., Singh, I., Singh, A. K., and Khan, M. (2009) Reduction of lipoxidative load by secretory phospholipase A₂ inhibition protects against neurovascular injury following experimental stroke in rat. *J. Neuroinflammation* 6, 21.

(156) Domoki, F., Zimmermann, A., Lenti, L., Toth-Szuki, V., Pardeike, J., Muller, R. H., and Bari, F. (2009) Secretory phospholipase A₂ inhibitor PX-18 preserves microvascular reactivity after cerebral ischemia in piglets. *Microvasc. Res.* 78, 212−217.

(157) Gentile, M. T., Reccia, M. G., Sorrentino, P. P., Vitale, E., Sorrentino, G., Puca, A. A., and Colucci-D'Amato, L. (2012) Role of cytosolic calcium-dependent phospholipase A₂ in Alzheimer's disease pathogenesis. *Mol. Neurobiol* 45, 596−604.

(158) Fonteh, A. N., Chiang, J., Cipolla, M., Hale, J., Diallo, F., Chirino, A., Arakaki, X., and Harrington, M. G. (2013) Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A₂ activity in Alzheimer's disease. *J. Lipid Res.* 54, 2884−2897.

(159) Simonyi, A., He, Y., Sheng, W., Sun, A. Y., Wood, W. G., Weisman, G. A., and Sun, G. Y. (2010) Targeting NADPH oxidase and phospholipases A₂ in Alzheimer's disease. *Mol. Neurobiol* 41, 73−86.

(160) Chalimoniuk, M., Stolecka, A., Cakala, M., Hauptmann, S., Schulz, K., Lipka, U., Leuner, K., Eckert, A., Muller, W. E., and Strosznajder, J. B. (2007) Amyloid beta enhances cytosolic phospholipase A₂ level and arachidonic acid release via nitric oxide in APP-transfected PC12 cells. *Acta Biochim. Polym.* 54, 611−623.

(161) Kriem, B., Sponne, I., Fifre, A., Malaplate-Armand, C., Lozac'h-Pillot, K., Koziel, V., Yen-Potin, F. T., Bihain, B., Oster, T., Olivier, J. L., and Pillot, T. (2005) Cytosolic phospholipase A₂ mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. *FASEB J.* 19, 85−87.

(162) Malaplate-Armand, C., Florent-Bechard, S., Youssef, I., Koziel, V., Sponne, I., Kriem, B., Leininger-Muller, B., Olivier, J. L., Oster, T., and Pillot, T. (2006) Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA₂-dependent sphingomyelinase-ceramide pathway. *Neurobiol. Dis.* 23, 178−189.

(163) Schaeffer, E. L., De-Paula, V. J., da Silva, E. R., de, A. N. B., Skaf, H. D., Forlenza, O. V., and Gattaz, W. F. (2011) Inhibition of phospholipase A₂ in rat brain decreases the levels of total Tau protein. *J. Neural Transm* 118, 1273−1279.

(164) Sundaram, J. R., Chan, E. S., Poore, C. P., Pareek, T. K., Cheong, W. F., Shui, G., Tang, N., Low, C. M., Wenk, M. R., and Kesavapany, S. (2012) Cdk5/p25-induced cytosolic PLA₂-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration. *J. Neurosci.* 32, 1020−1034.

(165) Defillipo, P. P., Raposo, A. H., Fedoce, A. G., Ferreira, A. S., Polonini, H. C., Gattaz, W. F., and Raposo, N. R. (2012) Inhibition of cPLA₂ and sPLA₂ activities in primary cultures of rat cortical neurons by Centella asiatica water extract. *Nat. Prod. Commun.* 7, 841−843.

(166) Lee, H. J., Bazinet, R. P., Rapoport, S. I., and Bhattacharjee, A. K. (2010) Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease. *Neurochem. Res.* 35, 613−619.

(167) Tariq, M., Khan, H. A., Al Moutaery, K., and Al Deeb, S. (2001) Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents. *Brain Res. Bull.* 54, 77−82.

(168) Yoshino, H., Tomiyama, H., Tachibana, N., Ogaki, K., Li, Y., Funayama, M., Hashimoto, T., Takashima, S., and Hattori, N. (2010) Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. *Neurology* 75, 1356−1361.

(169) Meng, Q., Luchtman, D. W., El Bahh, B., Zidichouski, J. A., Yang, J., and Song, C. (2010) Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. *Eur. J. Pharmacol.* 649, 127−134.

(170) Luchtman, D. W., Meng, Q., and Song, C. (2012) Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. *Behav. Brain Res.* 226, 386−396.

(171) Marusic, S., Leach, M. W., Pelker, J. W., Azoitei, M. L., Uozumi, N., Cui, J., Shen, M. W., DeClercq, C. M., Miyashiro, J. S., Carito, B. A., Thakker, P., Simmons, D. L., Leonard, J. P., Shimizu, T., and Clark, J. D. (2005) Cytosolic phospholipase A₂ α-deficient mice are resistant to experimental autoimmune encephalomyelitis. *J. Exp Med.* 202, 841−851.

(172) Marusic, S., Thakker, P., Pelker, J. W., Stedman, N. L., Lee, K. L., McKew, J. C., Han, L., Xu, X., Wolf, S. F., Borey, A. J., Cui, J., Shen, M. W., Donahue, F., Hassan-Zahraee, M., Leach, M. W., Shimizu, T., and Clark, J. D. (2008) Blockade of cytosolic phospholipase A₂ alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. *J. Neuroimmunol* 204, 29−37.

(173) Vana, A. C., Li, S., Ribeiro, R., Tchantchou, F., and Zhang, Y. (2011) Arachidonyl trifluoromethyl ketone ameliorates experimental autoimmune encephalomyelitis via blocking peroxynitrite formation in mouse spinal cord white matter. *Exp. Neurol.* 231, 45−55.

(174) Thakker, P., Marusic, S., Stedman, N. L., Lee, K. L., McKew, J. C., Wood, A., Goldman, S. J., Leach, M. W., Collins, M., Kuchroo, V. K., Wolf, S. F., Clark, J. D., and Hassan-Zahraee, M. (2011) Cytosolic phospholipase A₂α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs. *J. Immunol.* 187, 1986−1997.

(175) Cunningham, T. J., Yao, L., Oetinger, M., Cort, L., Blankenhorn, E. P., and Greenstein, J. I. (2006) Secreted phospholipase A₂ activity in experimental autoimmune encephalomyelitis and multiple sclerosis. *J. Neuroinflammation* 3, 26.

(176) Sun, Y., Li, X. Q., Sahbaie, P., Shi, X. Y., Li, W. W., Liang, D. Y., and Clark, J. D. (2012) miR-203 regulates nociceptive sensitization after incision by controlling phospholipase A₂ activating protein expression. *Anesthesiology* 117, 626−638.

(177) Yoo, S., Han, S., Park, Y. S., Lee, J. H., Oh, U., and Hwang, S. W. (2009) Lipoxygenase inhibitors suppressed carrageenan-induced Fos-expression and inflammatory pain responses in the rat. *Mol. Cells* 27, 417−422.

(178) Ma, M. T., Yeo, J. F., Shui, G., Wenk, M. R., and Ong, W. Y. (2012) Systems wide analyses of lipids in the brainstem during inflammatory orofacial pain - evidence of increased phospholipase A(2) activity. *Eur. J. Pain* 16, 38−48.

(179) Kim, D. H., Fitzsimmons, B., Hefferan, M. P., Svensson, C. I., Wancewicz, E., Monia, B. P., Hung, G., Butler, M., Marsala, M., Hua, X. Y., and Yaksh, T. L. (2008) Inhibition of spinal cytosolic phospholipase A(2) expression by an antisense oligonucleotide attenuates tissue injury-induced hyperalgesia. *Neuroscience 154*, 1077−1087.

(180) Tsuda, M., Hasegawa, S., and Inoue, K. (2007) P2X receptors-mediated cytosolic phospholipase A$_2$ activation in primary afferent sensory neurons contributes to neuropathic pain. *J. Neurochem. 103*, 1408−1416.

(181) Hasegawa, S., Kohro, Y., Tsuda, M., and Inoue, K. (2009) Activation of cytosolic phospholipase A$_2$ in dorsal root ganglion neurons by Ca^{2+}/calmodulin-dependent protein kinase II after peripheral nerve injury. *Mol. Pain 5*, 22.

(182) Ma, L., Uchida, H., Nagai, J., Inoue, M., Aoki, J., and Ueda, H. (2010) Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A$_2$ and autotaxin in nerve injury-induced neuropathic pain. *J. Pharmacol. Exp. Ther. 333*, 540−546.

(183) Ayoub, S. S., Yazid, S., and Flower, R. J. (2008) Increased susceptibility of annexin-A1 null mice to nociceptive pain is indicative of a spinal antinociceptive action of annexin-A1. *Br. J. Pharmacol. 154*, 1135−1142.

(184) Ma, L., Nagai, J., and Ueda, H. (2010) Microglial activation mediates de novo lysophosphatidic acid production in a model of neuropathic pain. *J. Neurochem. 115*, 643−653.

(185) Lino, R. C., Martins, F. I., Florentino, I. F., Nascimento, M. V., Galdino, P. M., Andrade, C. H., Rezende, K. R., Menegatti, R., and Costa, E. A. (2013) Anti-inflammatory effect of (*E*)-4-(3,7-dimethyl-locta-2,6-dienylamino)phenol, a new derivative of 4-nerolidylcatechol. *J. Pharm. Pharmacol. 65*, 133−141.

(186) Hibbeln, J. R., and Salem, N., Jr. (1995) Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. *Am. J. Clin. Nutr. 62*, 1−9.

(187) Lee, L. H., Tan, C. H., Shui, G., Wenk, M. R., and Ong, W. Y. (2012) Role of prefrontal cortical calcium independent phospholipase A(2) in antidepressant-like effect of maprotiline. *Int. J. Neuropsychopharmacol. 15*, 1087−1098.

(188) Kim, H. W., Rapoport, S. I., and Rao, J. S. (2011) Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. *Mol. Psychiatry 16*, 419−428.

(189) Rao, J. S., and Rapoport, S. I. (2009) Mood-stabilizers target the brain arachidonic acid cascade. *Curr. Mol. Pharmacol. 2*, 207−214.

(190) Stolk, P., Souverein, P. C., Wilting, I., Leufkens, H. G., Klein, D. F., Rapoport, S. I., and Heerdink, E. R. (2010) Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. *Prostaglandins Leukot. Essent. Fatty Acids 82*, 9−14.

(191) Rapoport, S. I. (2014) Lithium and the Other Mood Stabilizers Effective in Bipolar Disorder Target the Rat Brain Arachidonic Acid Cascade. *ACS Chem. Neurosci. 5*, 459−467.

(192) Horga, G., Bernacer, J., Dusi, N., Entis, J., Chu, K., Hazlett, E. A., Haznedar, M. M., Kemether, E., Byne, W., and Buchsbaum, M. S. (2011) Correlations between ventricular enlargement and gray and white matter volumes of cortex, thalamus, striatum, and internal capsule in schizophrenia. *Eur. Arch. Psychiatry Clin. Neurosci. 261*, 467−476.

(193) Garey, L. J., Ong, W. Y., Patel, T. S., Kanani, M., Davis, A., Mortimer, A. M., Barnes, T. R., and Hirsch, S. R. (1998) Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. *J. Neurol. Neurosurg. Psychiatry 65*, 446−453.

(194) Brunner, J., and Gattaz, W. F. (1995) Intracerebral injection of phospholipase A$_2$ inhibits dopamine-mediated behavior in rats: possible implications for schizophrenia. *Eur. Arch. Psychiatry Clin. Neurosci. 246*, 13−16.

(195) Brunner, J., and Gattaz, W. F. (1995) Intracerebroventricular injection of phospholipase A$_2$ inhibits apomorphine-induced locomotion in rats. *Psychiatry Res. 58*, 165−169.

(196) Eckert, G. P., Schaeffer, E. L., Schmitt, A., Maras, A., and Gattaz, W. F. (2011) Increased brain membrane fluidity in schizophrenia. *Pharmacopsychiatry 44*, 161−162.

(197) Smesny, S., Milleit, B., Nenadic, I., Preul, C., Kinder, D., Lasch, J., Willhardt, I., Sauer, H., and Gaser, C. (2010) Phospholipase A$_2$ activity is associated with structural brain changes in schizophrenia. *Neuroimage 52*, 1314−1327.

(198) Kim, H. W., Cheon, Y., Modi, H. R., Rapoport, S. I., and Rao, J. S. (2012) Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain. *Psychopharmacology (Berl.) 222*, 663−674.

(199) Brown, C. M., and Austin, D. W. (2011) Autistic disorder and phospholipids: A review. *Prostaglandins Leukot. Essent. Fatty Acids 84*, 25−30.

(200) Sudarov, A., Gooden, F., Tseng, D., Gan, W. B., and Ross, M. E. (2013) Lis1 controls dynamics of neuronal filopodia and spines to impact synaptogenesis and social behaviour. *EMBO Mol. Med. 5*, 591−607.

(201) Farooqui, A. A., Litsky, M. L., Farooqui, T., and Horrocks, L. A. (1999) Inhibitors of intracellular phospholipase A$_2$ activity: their neurochemical effects and therapeutical importance for neurological disorders. *Brain Res. Bull. 49*, 139−153.

(202) Farooqui, M. A., Al-Raisi, M., and Al-Moundhry, Z. (2002) Peripheral edema with Valproate therapy. *Neurosciences (Riyadh) 7*, 307−308.

(203) Miele, L. (2003) New weapons against inflammation: dual inhibitors of phospholipase A$_2$ and transglutaminase. *J. Clin. Invest. 111*, 19−21.

(204) Magrioti, V., and Kokotos, G. (2010) Phospholipase A$_2$ inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. *Expert Opin. Ther. Pat. 20*, 1−18.

(205) Dennis, E. A., Cao, J., Hsu, Y. H., Magrioti, V., and Kokotos, G. (2011) Phospholipase A$_2$ enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. *Chem. Rev. 111*, 6130−6185.

(206) Mouchlis, V. D., Barbayianni, E., Mavromoustakos, T. M., and Kokotos, G. (2011) The application of rational design on phospholipase A(2) inhibitors. *Curr. Med. Chem. 18*, 2566−2582.

(207) Magrioti, V., and Kokotos, G. (2013) Phospholipase A$_2$ inhibitors for the treatment of inflammatory diseases: a patent review (2010−present). *Expert Opin. Ther. Pat. 23*, 333−344.

(208) De-Paula, V. J., Schaeffer, E. L., Talib, L. L., Gattaz, W. F., and Forlenza, O. V. (2010) Inhibition of phospholipase A$_2$ increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. *Prostaglandins Leukot Essent Fatty Acids 82*, 57−60.

(209) Han, M. S., Lim, Y. M., Quan, W., Kim, J. R., Chung, K. W., Kang, M., Kim, S., Park, S. Y., Han, J. S., Park, S. Y., Cheon, H. G., Dal Rhee, S., Park, T. S., and Lee, M. S. (2011) Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance. *J. Lipid Res. 52*, 1234−1246.